WO2014082050A1 - Synergistic bacterial compositions and methods of production and use thereof - Google Patents

Synergistic bacterial compositions and methods of production and use thereof Download PDF

Info

Publication number
WO2014082050A1
WO2014082050A1 PCT/US2013/071758 US2013071758W WO2014082050A1 WO 2014082050 A1 WO2014082050 A1 WO 2014082050A1 US 2013071758 W US2013071758 W US 2013071758W WO 2014082050 A1 WO2014082050 A1 WO 2014082050A1
Authority
WO
WIPO (PCT)
Prior art keywords
type
composition
bacterial
bacteria
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/071758
Other languages
English (en)
French (fr)
Inventor
Geoffrey Von Maltzahn
Matthew R. HENN
Anthony Mario D'ONOFRIO
Kevin Daniel LITCOFSKY
David A. Berry
David Cook
Noubar B. Afeyan
John G. Aunins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seres Health Inc
Original Assignee
Seres Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seres Health Inc filed Critical Seres Health Inc
Priority to NZ709392A priority Critical patent/NZ709392A/en
Priority to BR112015011933A priority patent/BR112015011933A8/pt
Priority to KR1020157016626A priority patent/KR102426653B1/ko
Priority to SG11201503966PA priority patent/SG11201503966PA/en
Priority to RU2015124366A priority patent/RU2724666C2/ru
Priority to AU2013347805A priority patent/AU2013347805C1/en
Priority to JP2015544179A priority patent/JP6506173B2/ja
Priority to KR1020227025731A priority patent/KR102617655B1/ko
Priority to CN201380071190.XA priority patent/CN104955466A/zh
Priority to MX2015006491A priority patent/MX2015006491A/es
Priority to CA2892297A priority patent/CA2892297C/en
Priority to HK16106857.1A priority patent/HK1218836A1/zh
Priority to EP19194787.8A priority patent/EP3628161B1/en
Priority to EP13856249.1A priority patent/EP2953472A4/en
Priority to EP23160605.4A priority patent/EP4233545A3/en
Priority to US14/091,201 priority patent/US8906668B2/en
Priority to US14/221,190 priority patent/US9028841B2/en
Publication of WO2014082050A1 publication Critical patent/WO2014082050A1/en
Priority to US14/592,481 priority patent/US9533014B2/en
Priority to IL238973A priority patent/IL238973A0/en
Anticipated expiration legal-status Critical
Priority to US15/359,439 priority patent/US20170165302A1/en
Priority to AU2018204406A priority patent/AU2018204406B2/en
Priority to US16/223,008 priority patent/US10864235B2/en
Priority to AU2020201598A priority patent/AU2020201598C1/en
Priority to US17/120,666 priority patent/US11458174B2/en
Priority to US17/120,671 priority patent/US11464812B2/en
Priority to US17/120,647 priority patent/US11389490B2/en
Priority to US17/120,657 priority patent/US11458173B2/en
Priority to AU2022204478A priority patent/AU2022204478A1/en
Priority to US17/938,184 priority patent/US12083151B2/en
Priority to AU2024204663A priority patent/AU2024204663A1/en
Priority to US18/792,910 priority patent/US20250064869A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/127—Antibiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This application includes a Sequence Listing submitted electronically as a text file named 24845_US_CRF_sequence_listing.txt, created on November 25, 2013, with a size of 2,945,024 bytes. The sequence listing is incorporated by reference.
  • Mammals are colonized by microbes in the gastrointestinal (Gl) tract, on the skin, and in other epithelial and tissue niches such as the oral cavity, eye surface and vagina.
  • the gastrointestinal tract harbors an abundant and diverse microbial community. It is a complex system, providing an environment or niche for a community of many different species or organisms, including diverse strains of bacteria. Hundreds of different species may form a commensal community in the Gl tract in a healthy person, and this complement of organisms evolves from the time of birth to ultimately form a functionally mature microbial population by about 3 years of age. Interactions between microbial strains in these populations and between microbes and the host, e.g.
  • the host immune system shape the community structure, with availability of and competition for resources affecting the distribution of microbes.
  • resources may be food, location and the availability of space to grow or a physical structure to which the microbe may attach.
  • host diet is involved in shaping the Gl tract flora.
  • a healthy microbiota provides the host with multiple benefits, including colonization resistance to a broad spectrum of pathogens, essential nutrient
  • microbiota functions can be lost or deranged, resulting in increased susceptibility to pathogens, altered metabolic profiles, or induction of proinflammatory signals that can result in local or systemic inflammation or
  • the intestinal microbiota plays a significant role in the pathogenesis of many diseases and disorders, including a variety of pathogenic infections of the gut. For instance, patients become more susceptible to pathogenic infections when the normal intestinal microbiota has been disturbed due to use of broad-spectrum
  • Fecal transplantation has been shown to be an effective treatment for patients suffering from severe or refractory Gl infections by repopulating the gut with a diverse array of microbes that control key pathogens by creating an ecological environment inimical to their proliferation and survival. Such approaches have demonstrated significant potential to decrease host susceptibility to infection. Fecal transplantation, however, is considered to be a procedure of last resort because it has the potential to transmit infectious or allergenic agents between hosts, involves the transmission of potentially hundreds of unknown strains from donor to patient, and is difficult to perform on a mass scale. Additionally, fecal transplantation is inherently nonstandardized and different desired and/or undesired material may be transmitted in any given donation.
  • Fecal transplantation is not approved by the FDA and is unlikely to gain approval since the product cannot be standardized and characterized according to regulatory requirements for identity, potency, purity and safety. Thus, there is a need for defined compositions that can be used to decrease susceptibility to infection and/or that facilitate restoration of a healthy gut microbiota.
  • compositions comprising an effective amount of a bacterial composition comprising at least a first type of isolated bacterium capable of forming a spore and a second type of isolated bacterium capable of forming a spore, wherein the first type and the second type are not identical, and wherein at least one of the first type and the second type are capable of decreasing and/or inhibiting the growth and/or colonization of at least one type of pathogenic bacteria.
  • the bacterial composition comprises at least about 3, 4, 5, 6, 7, 8, 9, or 10 types of isolated bacteria.
  • the bacterial composition comprises at least about 3, 4, 5, 6, 7, 8, 9, or 10 types of isolated bacteria and at least 1 , 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the isolated bacteria are capable of forming spores. In an embodiment, the bacterial composition comprises at least about 5 types of isolated bacteria and at least 2 of the isolated bacteria are capable of forming spores.
  • the bacterial composition comprises: i) at least about 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30 or more types of isolated bacteria capable of forming spores, ii) at least about 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30 or more types of isolated bacteria not known to be capable of forming spores, or iii) any combination of i) and ii).
  • the first type and the second type are present in the composition in approximately equal concentrations.
  • the first type and the second type are present in the composition in not substantially equal concentrations.
  • the first type is present in the composition in at least about 150% the concentration of the second type, or wherein the second type is present in the composition in at least about 150% the concentration of the first type.
  • the composition consists essentially of: i) between two and about twenty types of isolated bacteria, wherein at least two types of isolated bacteria are
  • the first type of isolated bacterium and the second type of isolated bacterium are selected from Table 1 .
  • the first type of isolated bacterium and the second type of isolated bacterium comprise an operational taxonomic unit (OTU) distinction.
  • the OTU distinction comprises 16S rRNA sequence similarity below about 95% identity.
  • the first type of isolated bacterium and the second type of isolated bacterium independently comprise bacteria that comprise 16S rRNA sequence at least 95% identical to 16S rRNA sequence present in a bacterium selected from Table 3.
  • a combination of the first type and the second type are: i) cytotoxic, ii) cytostatic, iii) capable of decreasing the growth of the pathogenic bacterium, iv) capable of inhibiting the growth of the pathogenic bacterium, v) capable of decreasing the colonization of the pathogenic bacterium, vi) capable of inhibiting the colonization of the pathogenic bacterium, or vii) any combination of i)-vi).
  • the combination is capable of inhibiting proliferation of the pathogenic bacteria present at a concentration at least equal to the concentration of the
  • the combination is capable of inhibiting proliferation of the pathogenic bacterial present at a concentration at least about twice the concentration of the combination of the first type and the second type. In an embodiment, the combination is capable of inhibiting proliferation of the pathogenic bacterial present at a concentration at least about ten times the
  • the pathogenic bacterium is selected from the group consisting of Yersinia, Vibrio, Treponema, Streptococcus, Staphylococcus, Shigella, Salmonella, Rickettsia, Orientia, Pseudomonas, Neisseria, Mycoplasma, Mycobacterium, Listeria, Leptospira, Legionella, Klebsiella, Helicobacter, Haemophilus, Francisella, Escherichia, Ehrlichia, Enterococcus, Coxiella, Corynebacterium, Clostridium, Chlamydia, Chlamydophila, Campylobacter, Burkholderia, Brucella, Borrelia, Bordetella, Bifidobacterium, Bacillus, multi-drug resistant bacteria, Carbapenem-resistent Enterobacteriaceae (CRE), extended spectrum beta-lactam resistant Enterococci (ESBL), and vancomycin-
  • compositions comprising an effective amount of a bacterial composition comprising at least a first type of isolated bacterium and a second type of isolated bacterium, wherein only one of the first type and the second type are capable of forming a spore, and wherein at least one of the first type and the second type are capable of decreasing the growth and/or colonization of at least one type of pathogenic bacteria.
  • compositions comprising an effective amount of a bacterial composition comprising at least a first type of isolated bacterium and a second type of isolated bacterium, wherein the first type and the second type are not spores or known to be capable of forming a spore, and wherein at least one of the first type and the second type are capable of decreasing the growth and/or colonization of at least one type of pathogenic bacteria.
  • At least one of the first type and the second type are capable of reducing the growth rate of at least one type of pathogenic bacteria. In an embodiment, at least one of the first type and the second type are cytotoxic to at least one type of pathogenic bacteria. In an embodiment, at least one of the first type and the second type are cytostatic to at least one type of pathogenic bacteria. In an
  • the first type and the second type are selected from Table 1 .
  • the first type and the second type comprise different species.
  • the first type and the second type comprise different genera.
  • the first type and the second type comprise different families.
  • the first type and the second type comprise different orders.
  • compositions comprising an effective amount of a bacterial composition comprising at least a first type of isolated bacterium and a second type of isolated bacterium, wherein: i) the first type and the second type are independently capable of forming a spore; ii) only one of the first type and the second type are capable of forming a spore or iii) neither the first type nor the second type are capable of forming a spore, wherein the first type and the second type are not identical, wherein the first type and the second type are capable of functionally populating the gastrointestinal tract of a human subject to whom the composition is administered.
  • the functional populating of the gastrointestinal tract comprises preventing a dysbiosis of the gastrointestinal tract. In an embodiment, the functional populating of the gastrointestinal tract comprises treating a dysbiosis of the gastrointestinal tract. In an embodiment, the functional populating of the gastrointestinal tract comprises reducing the severity of a dysbiosis of the gastrointestinal tract. In an embodiment, the functional populating of the gastrointestinal tract comprises reducing one or more symptoms of a dysbiosis of the gastrointestinal tract. In an embodiment, the functional populating of the gastrointestinal tract comprises preventing growth and/or colonization of the gastrointestinal tract by a pathogenic bacterium. In an embodiment, the functional populating of the gastrointestinal tract comprises reducing growth and/ or colonization of the gastrointestinal tract by a pathogenic bacterium.
  • the functional populating of the gastrointestinal tract comprises reducing the number of one or more types of pathogenic bacteria in the gastrointestinal tract. In an embodiment, the functional populating of the gastrointestinal tract comprises increasing the number of one or more non-pathogenic bacteria in the gastrointestinal tract.
  • the bacterial composition comprises 0, 1 , 2, 3 or greater than 3 types of isolated bacteria capable of forming spores. In an embodiment, the bacterial composition comprises at least about 5 types of isolated bacteria capable of forming spores. In an embodiment, the bacterial composition comprises at least about 7 types of isolated bacteria capable of forming spores. In an embodiment, the first type and the second type are present in the composition in not substantially equal concentrations.
  • the first type and the second type are present in the composition in approximately equal concentrations. In an embodiment, the first type is present in the composition in at least about 150% the concentration of the second type. In an embodiment, the second type is present in the composition in at least about 150% the concentration of the first type. In an embodiment, the composition consists essentially of between two and about ten types of isolated bacteria, wherein at least one type of isolated bacteria are
  • the first type of isolated bacterium and the second type of isolated bacterium are selected from Table 1 .
  • the first type of isolated bacterium and the second type of isolated bacterium comprise an operational taxonomic unit (OTU) distinction.
  • the OTU distinction comprises 16S rRNA sequence similarity below about 95% identity.
  • the first type of isolated bacterium and the second type of isolated bacterium independently comprise bacteria that comprise 16S rRNA sequence at least 95% identical to 16S rRNA sequence present in a bacterium selected from Table 3.
  • a combination of the first type and the second type are cytotoxic or cytostatic to the pathogenic bacterium.
  • the combination is capable of inhibiting proliferation of the pathogenic bacteria present at a concentration at least equal to the concentration of the combination of the first type and the second type. In an embodiment, the combination is capable of inhibiting proliferation of the pathogenic bacterial present at a concentration at least about twice the concentration of the combination of the first type and the second type. In an embodiment, the combination is capable of inhibiting proliferation of the pathogenic bacteria present at a concentration at least about ten times the concentration of the combination of the first type and the second type.
  • the pathogenic bacterium is selected from the group consisting of Yersinia, Vibrio, Treponema, Streptococcus, Staphylococcus, Shigella, Salmonella, Rickettsia, Orientia, Pseudomonas, Neisseria, Mycoplasma,
  • Mycobacterium Listeria, Leptospira, Legionella, Klebsiella, Helicobacter, Haemophilus, Francisella, Escherichia, Ehrlichia, Enterococcus, Coxiella, Corynebacterium,
  • CRE Carbapenem-resistent Enterobacteriaceae
  • ESBL extended spectrum beta-lactam resistant Enterococci
  • VRE vancomycin-resistant Enterococci
  • the first type and the second type synergistically interact to be cytotoxic to the pathogenic bacterium.
  • the dose unit comprises at least 1x10 4 , 1 x10 5 , 1 x10 6 , 1x10 7 , 1 x10 8 , 1 x10 9 , 1 x10 10 , 1 x10 11 or greater than 1x10 11 colony forming units (CFUs) of either spores or vegetative bacterial cells.
  • the dose unit comprises a pharmaceutically acceptable excipient, an enteric coating or a combination thereof.
  • the dose unit further comprises a drug selected from corticosteroids, mesalazine, mesalamine, sulfasalazine, sulfasalazine derivatives, immunosuppressive drugs, cyclosporin A, mercaptopurine, azathiopurine, prednisone, methotrexate, antihistamines, glucocorticoids, epinephrine, theophylline, cromolyn sodium, anti-leukotrienes, anti-cholinergic drugs for rhinitis, anticholinergic decongestants, mast-cell stabilizers, monoclonal anti-lgE antibodies, vaccines, and combinations thereof.
  • the dose unit is formulated for oral administration, rectal administration, or the combination of oral and rectal
  • kits comprising in one or more containers: a first purified population of a first type of bacterial spores substantially free of viable vegetal bacterial cells; and a second purified population of a second type of bacterial spores substantially free of viable vegetal bacterial cells, wherein the first type and the second type of bacterial spores are not identical, and wherein the first type and the second type of bacterial spores, when co-localized in a target region of a gastrointestinal tract of a human subject in need thereof, are capable of functionally populating the gastrointestinal tract.
  • the first purified population and the second purified population are present in a single container.
  • the first purified population and the second purified population are present in two containers. In an embodiment, the first purified population and the second purified population are lyophilized or substantially dehydrated. In an embodiment, the kit further comprises in one or more containers an effective amount of an anti-bacterial agent, an effective amount of an anti-viral agent, an effective amount of an anti-fungal agent, an effective amount of an anti-parasitic agent, or a combination thereof in one or more containers. In an embodiment, the kit further comprises a pharmaceutically acceptable excipient or diluent.
  • compositions of the invention comprising an effective amount of the compositions of the invention, and further comprising an effective amount of an anti-bacterial agent, an effective amount of an anti-fungal agent, an effective amount of an anti-viral agent, an effective amount of an anti-parasitic agent.
  • comestible products comprising a first purified
  • first type of bacterial spores and a second purified population of a second type of bacterial spores, wherein the first type and the second type of bacterial spores are not identical, wherein the comestible product is substantially free of viable vegetal bacterial cells, and wherein the first type and the second type of bacterial spores, when administered to a human subject in need thereof, are capable of functionally populating the gastrointestinal tract of the human subject.
  • the comestible product comprises a food or food additive, a beverage or beverage additive, or a medical food.
  • the comestible product comprises at least 1 x10 4 , 1x10 5 , 1 x10 6 , 1 x10 7 , 1x10 8 , 1 x10 9 , 1 x10 10 , 1 x10 1 1 or greater than 1 x10 11 colony forming units (CFUs) of viable spores.
  • CFUs colony forming units
  • the comestible product comprises a first type of bacterial spores and a second type of bacterial spores selected from Table 1 , or where the first type of bacterial spores and the second type of bacterial spores independently comprise bacterial spores that comprise 16S rRNA sequence at least 95% identical to 16S rRNA sequence present in a bacterium selected from Table 3.
  • Also provided are methods comprising administering to a human subject in need thereof an effective amount of a bacterial composition comprising at least a first type of isolated bacterium and a second type of isolated bacterium, wherein: the first type and the second type are independently capable of forming a spore; only one of the first type and the second type are capable of forming a spore or neither the first type nor the second type are capable of forming a spore, wherein the first type and the second type are not identical, and wherein at least one of the first type and the second type exert an inhibitory-effect on a pathogenic bacterium present in the gastrointestinal tract of the human subject, such that the number of pathogenic bacteria present in the gastrointestinal tract is not detectably increased or is detectably decreased over a period of time.
  • the human subject is diagnosed as having a dysbiosis of the gastrointestinal tract.
  • a pathogenic bacterium selected from the group consisting of Yersinia, Vibrio, Treponema, Streptococcus, Staphylococcus, Shigella, Salmonella, Rickettsia, Orientia, Pseudomonas, Neisseria, Mycoplasma, Mycobacterium, Listeria, Leptospira, Legionella, Klebsiella, Helicobacter, Haemophilus, Francisella, Escherichia, Ehrlichia, Enterococcus, Coxiella, Corynebacterium, Clostridium, Chlamydia, Chlamydophila, Campylobacter, Burkholderia, Brucella, Borrelia, Bordetella, Bifidobacterium, Bacillus, multi-drug resistant bacteria, Carbapenem
  • the bacterial composition is administered simultaneously with i) an antibiotic, ii) a prebiotic, or iii) a combination of i) and ii). In an embodiment, the bacterial composition is administered prior to administration of i) an antibiotic, ii) a prebiotic, or iii) a combination of i) and ii). In an embodiment, the bacterial composition is administered subsequent to administration of i) an antibiotic, ii) a prebiotic, or iii) a combination of i) and ii). In an embodiment, the number of pathogenic bacterium present in or excreted from the gastrointestinal tract of the human subject is detectably reduced within one month, within two weeks, or within one week of administration of the bacterial composition. In an embodiment, the number of
  • the pathogenic bacterium present in or excreted from the gastrointestinal tract of the human subject is detectably reduced within three days, two days or one day of administration of the bacterial composition.
  • the human subject is detectably free of the pathogenic bacterium within one month, two weeks, one week, three days or one day of administration of the bacterial composition.
  • the bacterial composition comprises at least about 3, 4, 5, 6, 7, 8, 9, or 10 types of isolated bacteria.
  • the bacterial composition comprises at least about 3, 4, 5, 6, 7, 8, 9, or 10 types of isolated bacteria and at least 1 , 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the isolated bacteria are capable of forming spores.
  • the bacterial composition comprises at least about 5 types of isolated bacteria and at least 2 of the isolated bacteria are capable of forming spores.
  • the bacterial composition comprises: i) at least about 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30 or more types of isolated bacteria capable of forming spores, ii) at least about 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30 or more types of isolated bacteria not known to be capable of forming spores, or iii) any combination of i) and ii).
  • the bacterial composition comprises at least about 5 types of isolated bacteria and at least 1 of the isolated bacteria are capable of forming spores. In an embodiment, the bacterial composition comprises at least about 5 types of isolated bacteria and at least 1 of the isolated bacteria is not capable of forming spores. In an embodiment, the bacterial composition comprises at least about 3, 4, 5, 6, 7, 8, 9 or 10 types of isolated bacteria, wherein i) at least 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 types of isolated bacteria are capable of forming spores, ii) at least 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 types of isolated bacteria are not capable of forming spores, or iii) any combination of i) and ii).
  • the first type and the second type are present in the composition in approximately equal concentrations. In an embodiment, the first type and the second type are present in the composition in not substantially equal concentrations. In an embodiment, the first type is present in the composition in at least about 150% the concentration of the second type, or wherein the second type is present in the composition in at least about 150% the concentration of the first type. In an embodiment, the composition consists essentially of between two and about ten types of isolated bacteria, wherein at least two types of isolated bacteria are independently capable of spore formation. In an embodiment, the composition consists essentially of between two and about ten types of isolated bacteria, wherein at least two types of isolated bacteria are not capable of spore formation.
  • the first type of isolated bacterium and the second type of isolated bacterium are selected from Table 1 .
  • the first type of isolated bacterium and the second type of isolated bacterium comprise an operational taxonomic unit (OTU) distinction.
  • the OTU distinction comprises 18S rRNA sequence similarity below about 95% identity.
  • the first type of isolated bacterium and the second type of isolated bacterium independently comprise bacteria that comprise 16S rRNA sequence at least 95% identical to 16S rRNA sequence present in a bacterium selected from Table 3.
  • combination of the first type and the second type are cytotoxic or cytostatic to the pathogenic bacterium.
  • the combination is capable of inhibiting proliferation of the pathogenic bacterial present at a concentration at least equal to the concentration of the combination of the first type and the second type.
  • the combination is capable of inhibiting proliferation of the pathogenic bacterial present at a concentration at least about twice the concentration of the combination of the first type and the second type. In an embodiment, the combination is capable of inhibiting proliferation of the pathogenic bacterial present at a concentration at least about ten times the concentration of the combination of the first type and the second type.
  • the pathogenic bacterium is selected from the group consisting of Yersinia, Vibrio, Treponema, Streptococcus, Staphylococcus, Shigella, Salmonella, Rickettsia, Orientia, Pseudomonas, Neisseria, Mycoplasma,
  • Mycobacterium Listeria, Leptospira, Legionella, Klebsiella, Helicobacter, Haemophilus, Francisella, Escherichia, Ehrlichia, Enterococcus, Coxiella, Corynebacterium,
  • CRE Carbapenem-resistent Enterobacteriaceae
  • ESBL extended spectrum beta-lactam resistant Enterococci
  • VRE vancomycin-resistant Enterococci
  • the first type and the second type synergistically interact to be cytotoxic to the pathogenic bacterium.
  • Also provided are methods of functionally populating the gastrointestinal tract of a human subject comprising administering to the subject an effective amount of a bacterial composition comprising at least a first type of isolated bacterium and a second type of isolated bacterium, wherein i) the first type and the second type are independently capable of forming a spore; ii) only one of the first type and the second type are capable of forming a spore or iii) neither the first type nor the second type are capable of forming a spore, wherein the first type and the second type are not identical, under conditions such that the first type and the second type functionally populate the gastrointestinal tract of the human subject.
  • the bacterial composition is orally administered, rectally administered, or the combination of orally and rectally administered. In an embodiment, the bacterial composition is topically or nasally administered or inhaled.
  • the first type of isolated bacteria and the second type of isolated bacteria are selected from Table 1 .
  • the bacterial composition consists essentially of spores, wherein the spores comprise spores of the first type of isolated bacteria and spores of the second type of isolated bacteria.
  • the first type of isolated bacteria and the second type of isolated bacteria independently comprise bacterial spores that comprise 16S rRNA sequence at least 95% identical to 16S rRNA sequence present in a bacterium selected from Table 3.
  • the functional populating of the gastrointestinal tract comprises preventing a dysbiosis of the gastrointestinal tract. In an embodiment, the functional populating of the gastrointestinal tract comprises treating a dysbiosis of the gastrointestinal tract. In an embodiment, the functional populating of the gastrointestinal tract comprises reducing the severity of a dysbiosis of the gastrointestinal tract. In an embodiment, the functional populating of the gastrointestinal tract comprises reducing one or more symptoms of a dysbiosis of the gastrointestinal tract. In an embodiment, the functional populating of the gastrointestinal tract comprises preventing colonization of the gastrointestinal tract by a pathogenic bacterium. In an embodiment, the functional populating of the gastrointestinal tract comprises reducing colonization of the
  • the functional populating of the gastrointestinal tract comprises reducing the number of one or more types of pathogenic bacteria in the gastrointestinal tract. In an embodiment, the functional populating of the gastrointestinal tract comprises increasing the number of one or more non-pathogenic bacteria in the gastrointestinal tract.
  • the bacterial composition comprises at least about 3, 5, 7 or 9 types of isolated bacteria capable of forming spores. In an embodiment, the bacterial
  • composition comprises at least about 5 types of isolated bacteria and at least 20% of the isolated bacteria are capable of forming spores.
  • the bacterial composition comprises at least about 5 types of isolated bacteria and at least 2 of the isolated bacteria are capable of forming spores.
  • the bacterial composition comprises at least about 3, 4, 5, 6, 7, 8, 9 or 10 types of isolated bacteria, wherein i) at least 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 types of isolated bacteria are capable of forming spores, ii) at least 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 types of isolated bacteria are not capable of forming spores, or iii) any combination of i) and ii).
  • the first type and the second type are present in the composition in approximately equal concentrations. In an embodiment, the first type and the second type are present in the composition in not substantially equal concentrations. In an embodiment, the first type is present in the composition in at least about 150% the concentration of the second type, or wherein the second type is present in the composition in at least about 150% the concentration of the first type. In an embodiment, the composition consists essentially of between two and about ten types of isolated bacteria, wherein i) at least one type of isolated bacteria is capable of spore formation, ii) at least one type of isolated bacteria is not capable of spore formation, or iii) a combination of i) and ii). In an embodiment, a combination of the first type and the second type are inhibitory to the pathogenic bacterium. In an embodiment, the combination reduces the growth rate of the
  • the combination is cytostatic or cytotoxic to the pathogenic bacterium. In an embodiment, the combination is capable of inhibiting growth of the pathogenic bacterial present at a concentration at least equal to the concentration of the combination of the first type and the second type. In an
  • the combination is capable of inhibiting growth of the pathogenic bacterial present at a concentration at least about twice the concentration of the combination of the first type and the second type. In an embodiment, the combination is capable of inhibiting proliferation of the pathogenic bacterial present at a concentration at least about ten times the concentration of the combination of the first type and the second type.
  • the pathogenic bacterium is selected from the group consisting of Yersinia, Vibrio, Treponema, Streptococcus, Staphylococcus, Shigella, Salmonella, Rickettsia, Orientia, Pseudomonas, Neisseria, Mycoplasma, Mycobacterium, Listeria, Leptospira, Legionella, Klebsiella, Helicobacter, Haemophilus, Francisella, Escherichia, Ehrlichia, Enterococcus, Coxiella, Corynebacterium, Clostridium, Chlamydia,
  • Chlamydophila Campylobacter, Burkholderia, Brucella, Borrelia, Bordetella
  • Bifidobacterium Bacillus, multi-drug resistant bacteria, Carbapenem-resistent
  • the first type and the second type synergistically interact to reduce or inhibit the growth of the pathogenic bacterium. In an embodiment, the first type and the second type
  • the method comprises administering to the human subject a single dose unit comprising at least 1 x10 4 , 1 x10 5 , 1 x10 6 , 1 x10 7 , 1 x10 8 , 1 x10 9 , 1 x10 10 , 1 x10 1 1 or greater than 1 x10 11 colony forming units (CFUs) of viable bacteria.
  • the dose unit comprises a bacterial population substantially in the form of spores.
  • the dose unit comprises a pharmaceutically acceptable excipient and/or an enteric coating.
  • the unit dose is formulated for oral administration, rectal administration, or the combination of oral and rectal administration.
  • the unit dose is formulated for topical or nasal administration or for inhalation.
  • kits for reducing the number of pathogenic bacteria present in the gastrointestinal tract of a human subject comprising administering to the subject an effective amount of a pharmaceutical formulation comprising an effective amount of the composition of any one of claims 1 , 21 , 22 or 31 , and further comprising an effective amount of an anti-microbial agent, under conditions such that the number of pathogenic bacteria present in the gastrointestinal tract of the human subject is reduced within about one month of administration of the
  • the number of pathogenic bacteria present in the gastrointestinal tract of the human subject is reduced within about two weeks of administration of the pharmaceutical formulation. In an embodiment, the number of pathogenic bacteria present in the gastrointestinal tract of the human subject is reduced within about one week of administration of the pharmaceutical formulation. In an embodiment, the number of pathogenic bacteria present in the gastrointestinal tract of the human subject is reduced within about three days of administration of the pharmaceutical formulation. In an embodiment, the number of pathogenic bacteria present in the gastrointestinal tract of the human subject is reduced within about one day of administration of the pharmaceutical formulation.
  • the antimicrobial agent comprises anti-bacterial agent. In an embodiment, the anti-microbial agent comprises anti-fungal agent. In an embodiment, the anti-microbial agent comprises anti-viral agent. In an embodiment, the anti-microbial agent comprises antiparasitic agent.
  • a comestible product comprising combining with a comestible carrier a first purified population comprising at least a first type of isolated bacterium and a second purified population comprising at least a second type of isolated bacterium, wherein: i) the first type and the second type are independently capable of forming a spore; ii) only one of the first type and the second type are capable of forming a spore or iii) neither the first type nor the second type are capable of forming a spore, wherein the first type and the second type of bacteria are not identical, wherein the comestible product is substantially free of non- comestible materials.
  • the comestible product is substantially free of viable vegetal bacterial cells.
  • the viable spores when the comestible product is consumed by a human subject in need thereof, are capable of functionally populating the gastrointestinal tract of the human subject.
  • the comestible product comprises a food or food additive.
  • the comestible product comprises a beverage or beverage additive.
  • the comestible product comprises a medical food.
  • the comestible product comprises at least 1 x10 4 , 1 x10 5 , 1 x10 6 , 1 x10 7 , 1 x10 8 , 1 x10 9 , 1 x10 10 , 1 x10 11 or greater than 1 x10 11 colony forming units (CFUs) of viable spores.
  • spores are of a bacterium selected from Table 1 .
  • the first purified population and the second purified population independently comprise bacterial spores that comprise 16S rRNA sequence at least 95% identical to 16S rRNA sequence present in a bacterium selected from Table 3.
  • Also provided are methods of reducing the abundance of a pathogen in the gastrointestinal tract of a patient comprising administering the composition of claim 1 in a therapeutically effective amount and allowing the bacterial composition to compete with the pathogen in the gastrointestinal tract of a patient.
  • the composition of claim 1 is administered in a therapeutically effective amount and allowing the bacterial composition to reduce the diarrheal effect of a pathogen in the gastrointestinal tract of a patient.
  • the pathogen is
  • Aeromonas hydrophila Campylobacter fetus, Plesiomonas shigelloides, Bacillus cereus, Campylobacter jejuni, Clostridium botulinum, Clostridium difficile, Clostridium
  • the pathogen is Clostridium difficile, Salmonella typhi, Shigella spp., Staphylococcus spp., Staphylococcus aureus, Vibrio spp., Vibrio cholerae, Vibrio parahaemolyticus, Vibrio vulnificus, Yersinia enterocolitica, multi-drug resistant bacteria, Carbapenem-resistent Enterobacteriaceae (CRE), and vancomycin-resistant Enterococci (VRE).
  • the pathogen is Clostridium difficile, Salmonella typhi, Shigella spp., Staphylococcus spp., Staphylococcus aureus, Vibrio spp., Vibrio cholerae, Vibrio parahaemolyticus, Vibrio vulnificus, Yersinia enterocolitica, multi-drug resistant bacteria, Carbapenem-resistent Enterobacteriaceae (C
  • the pathogen is Clostridium difficile.
  • the composition is administered orally.
  • compositions comprising a first purified bacterial population capable forming spores consisting of Collinsella aerofaciens and a second purified bacterial population consisting of a species selected from Table 1 or Table 4, wherein at least one of the first type and the second type are cytotoxic or cytostatic to a pathogenic bacterium.
  • a synergistic combination of the first bacterial spore population and the second bacterial spore population are cytotoxic or cytostatic to the pathogenic bacterium.
  • the combination is capable of inhibiting proliferation of the pathogenic bacterial present at a concentration at least equal to the concentration of the combination of the first type and the second type.
  • the combination is capable of inhibiting proliferation of the pathogenic bacterial present at a concentration at least about twice the concentration of the combination of the first type and the second type. In an embodiment, the combination is capable of inhibiting proliferation of the pathogenic bacterial present at a concentration at least about ten times the concentration of the combination of the first type and the second type.
  • the pathogenic bacterium is selected from the group consisting of Yersinia, Vibrio, Treponema, Streptococcus, Staphylococcus, Shigella, Salmonella, Rickettsia, Pseudomonas, Neisseria, Mycoplasma, Mycobacterium, Listeria, Leptospira, Legionella, Helicobacter, Haemophilus, Francisella, Escherichia,
  • the pathogenic bacterium is Clostridium pere.
  • the first bacterial spore population and the second bacterial spore population synergistically interact to be cytotoxic to the pathogenic bacterium.
  • the first bacterial spore population and the second bacterial spore population synergistically interact to be cytostatic to the pathogenic bacterium.
  • the bacterial composition comprises at least about 3 types of isolated bacteria capable of forming spores.
  • the bacterial composition comprises at least about 5 types of isolated bacteria capable of forming spores.
  • the first bacterial spore population and the second bacterial spore population are present in the composition in approximately equal concentrations.
  • the composition consists essentially of between two and about ten bacterial spore populations of isolated bacteria.
  • compositions comprising a first purified bacterial spore population consisting of bacteria comprising 16S rRNA
  • the first type and the second type are cytotoxic or cytostatic to a pathogenic bacterium.
  • a synergistic combination of the first type and the second type are cytotoxic or cytostatic to the pathogenic bacterium.
  • the combination is capable of inhibiting proliferation of the pathogenic bacterial present at a concentration at least equal to the concentration of the combination of the first type and the second type.
  • the first type and the second type are cytotoxic or cytostatic to the pathogenic bacterium.
  • the first purified bacterial spore population and the second purified bacterial spore population are capable of functionally populating the gastrointestinal tract of a human subject to whom the composition is administered.
  • the functional populating of the gastrointestinal tract comprises preventing, treating, reducing the severity of or reducing a symptom of a dysbiosis of the gastrointestinal tract.
  • the functional populating of the gastrointestinal tract comprises i) reducing the number of one or more types of pathogenic bacteria in the
  • the composition further comprises an effective amount of an anti-bacterial agent, an anti-fungal agent, an antiviral agent or an anti-parastic agent.
  • Also provided are methods of treating or preventing a recurrence of a Clostridium difficile infection comprising administering to a human subject in need thereof an effective amount of the therapeutic composition of claim 14 under conditions such that the first purified bacterial spore population and the second purified bacterial spore population exert a cytotoxic or cytostatic effect on a pathogenic bacterium present in the gastrointestinal tract of the human subject, such that the number of Clostridium difficile bacteria present in the gastrointestinal tract is not detectably increased or is detectably decreased over a period of time.
  • Clostridium difficile bacteria present in or excreted from the gastrointestinal tract of the human subject is detectably reduced within one month of administration of the bacterial composition.
  • the first purified bacterial spore population and the second purified bacterial spore population synergistically interact to be cytotoxic and/or cytostatic to the Clostridium difficile bacteria.
  • the therapeutic composition is orally administered.
  • the therapeutic composition comprises a medical food.
  • kits comprising in one or more containers: a first purified population of a first type of bacteria capable of forming spores; and a second purified population of a second type of bacteria capable of forming spores, wherein the first type and the second type are not identical, and wherein the first type and the second type, when co-localized in a target region of a gastrointestinal tract of a human subject in need thereof, are capable of functionally populating the
  • the first purified population and the second purified population are present in a single container.
  • the kit is formulated for use as a nutritional supplement and optionally comprising a prebiotic material.
  • FIG. 1A provides a schematic of 16S rRNA gene and denotes the coordinates of hypervariable regions 1 -9 (V1 -V9). Coordinates of V1 -V9 are 69-99, 137- 242, 433-497, 576-682, 822-879, 986-1043, 1 1 17-1 173, 1243-1294, and 1435-1465 respectively, based on numbering using E. coli system of nomenclature defined by Brosius et al., Complete nucleotide sequence of a 16S ribosomal RNA gene (16S rRNA) from Escherichia coli, PNAS 75(10):4801 -4805 (1978). Figure 1 B highlights in bold the nucleotide sequences for each hypervariable region in the exemplary reference E. coli 16S sequence described by Brosius et al.
  • Table 1 provides bacterial species and Operational Taxonomic Units (OTUs) of the bacterial compositions of the present invention, including taxonometric status and the ability of the OTU to form a viable spore as provided herein.
  • OTUs Operational Taxonomic Units
  • Table 2 provides representative combinations of the bacterial
  • compositions of the present invention are compositions of the present invention.
  • Table 3 provides 16S rRNA sequences of the bacterial species and Operational Taxonomic Units (OTUs) of the bacterial compositions of the present invention.
  • Table 3 is provided in the CRF version of the Sequence Listing as SEQ ID NOS 1 -1 ,864.
  • Table 4 provides taxonometric status, exemplary phylogenetic surrogacy and 16S rRNA sequences of exemplary bacterial compositions of the present invention. Table 4 is provided in the CRF version of the Sequence Listing as SEQ ID NOS 1 ,865- 1 ,915.
  • Table 5 demonstrates the efficacy of exemplary bacterial compositions of the present invention in inhibiting a pathogenic bacterium.
  • Table 6 demonstrates the efficacy of exemplary bacterial compositions of the present invention in inhibiting a pathogenic bacterium.
  • Table 7 provides representative bacterial pathogens.
  • Table 8 provides representative human diseases, disorders and conditions for which the provided bacterial compositions are useful.
  • Table 9 provides representative human diseases, disorders and conditions for which the provided bacterial compositions are useful.
  • Microbiota refers to the communities of microbes that live in or on the patient's body, both sustainably and transiently, including eukaryotes, archaea, bacteria, and viruses (including bacterial viruses (i.e., phage)).
  • “Dysbiosis” refers to a state of the microbiota or microbiome of the gut or other body area, including mucosal or skin surfaces in which the normal diversity and/or function of the ecological network is disrupted. Any disruption from the preferred (e.g., ideal) state of the microbiota can be considered a dysbiosis, even if such dysbiosis does not result in a detectable decrease in health.
  • Dysbiosis may be unhealthy, it may be unhealthy under only certain conditions, or it may prevent a subject from becoming healthier.
  • Dysbiosis may be due to a decrease in diversity, the overgrowth of one or more pathogens or pathobionts, symbiotic organisms able to cause disease only when certain genetic and/or environmental conditions are present in a patient, or the shift to an ecological network that no longer provides a beneficial function to the host and therefore no longer promotes health.
  • a "spore” or a population of “spores” includes bacteria (or other single- celled organisms) that are generally viable, more resistant to environmental influences such as heat and bacteriocidal agents than vegetative forms of the same bacteria, and typically capable of germination and out-growth.
  • "Spore-formers” or bacteria “capable of forming spores” are those bacteria containing the genes and other necessary abilities to produce spores under suitable environmental conditions.
  • pathogen in reference to a bacterium or any other organism or entity includes any such organism or entity that is capable of causing or affecting a disease, disorder or condition of a host organism containing the organism or entity.
  • isolated encompasses a bacterium or other entity or substance that has been (1 ) separated from at least some of the components with which it was associated when initially produced (whether in nature or in an experimental setting), and/or (2) produced, prepared, purified, and/or manufactured by the hand of man.
  • Isolated bacteria may be separated from at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or more of the other components with which they were initially associated. In some embodiments, isolated bacteria are more than about 80%, about 85%, about 90%, about 91 %, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99% pure. As used herein, a substance is "pure" if it is substantially free of other components.
  • purify refers to a bacterium or other material that has been separated from at least some of the components with which it was associated either when initially produced or generated (e.g., whether in nature or in an experimental setting), or during any time after its initial production.
  • a bacterium or a bacterial population may be considered purified if it is isolated at or after production, such as from a material or environment containing the bacterium or bacterial population, and a purified bacterium or bacterial population may contain other materials up to about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or above about 90% and still be considered "isolated.”
  • purified bacteria and bacterial populations are more than about 80%, about 85%, about 90%, about 91 %, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99% pure.
  • the one or more bacterial types present in the composition can be independently purified from one or more other bacteria produced and/or present in the material or environment containing the bacterial type.
  • Bacterial compositions and the bacterial components thereof are generally purified from residual habitat products.
  • Demonstrations of pathogen inhibition such as decrease in the growth of a pathogenic bacterium or reduction in the level of colonization of a pathogenic bacterium are provided herein and otherwise recognized by one of ordinary skill in the art.
  • Inhibition of a pathogenic bacterium's "growth” may include inhibiting the increase in size of the pathogenic bacterium and/or inhibiting the proliferation (or multiplication) of the pathogenic bacterium.
  • Inhibition of colonization of a pathogenic bacterium may be demonstrated by measuring the amount or burden of a pathogen before and after a treatment.
  • An "inhibition" or the act of “inhibiting” includes the total cessation and partial reduction of one or more activities of a pathogen, such as growth, proliferation, colonization, and function.
  • the "colonization" of a host organism includes the non-transitory residence of a bacterium or other microscopic organism.
  • "reducing colonization" of a host subject's gastrointestinal tract (or any other microbiotal niche) by a pathogenic bacterium includes a reduction in the residence time of the pathogen in the
  • Measuring reductions of adherent pathogens may be demonstrated, e.g., by a biopsy sample, or reductions may be measured indirectly, e.g., by measuring the pathogenic burden in the stool of a mammalian host.
  • a "combination" of two or more bacteria includes the physical co-existence of the two bacteria, either in the same material or product or in physically connected products, as well as the temporal co-administration or co-localization of the two bacteria.
  • a "cytotoxic” activity or bacterium includes the ability to kill a bacterial cell, such as a pathogenic bacterial cell.
  • a "cytostatic” activity or bacterium includes the ability to inhibit, partially or fully, growth, metabolism, and/or proliferation of a bacterial cell, such as a pathogenic bacterial cell.
  • composition or other material provided herein does not have a substantial amount of a non-comestible product, e.g., a product or material that is inedible, harmful or otherwise undesired in a product suitable for administration, e.g., oral administration, to a human subject.
  • a non-comestible product e.g., a product or material that is inedible, harmful or otherwise undesired in a product suitable for administration, e.g., oral administration, to a human subject.
  • Non-comestible products are often found in preparations of bacteria from the prior art.
  • Microbiome refers to the genetic content of the communities of microbes that live in and on the human body, both sustainably and transiently, including
  • RNA such as micro RNA and ribosomal RNA
  • epigenome eukaryotes, archaea, bacteria, and viruses (including bacterial viruses (i.e., phage)
  • genetic content includes genomic DNA, RNA such as micro RNA and ribosomal RNA, the epigenome, plasmids, and all other types of genetic information.
  • Residual habitat products refers to material derived from the habitat for microbiota within or on a human or animal.
  • microbiota live in feces in the gastrointestinal tract, on the skin itself, in saliva, mucus of the respiratory tract, or secretions of the genitourinary tract (i.e., biological matter associated with the microbial community).
  • Substantially free of residual habitat products means that the bacterial composition no longer contains the biological matter associated with the microbial environment on or in the human or animal subject and is 100% free, 99% free, 98% free, 97% free, 96% free, or 95% free of any contaminating biological matter associated with the microbial community.
  • Residual habitat products can include abiotic materials (including undigested food) or it can include unwanted microorganisms. Substantially free of residual habitat products may also mean that the bacterial composition contains no detectable cells from a human or animal and that only microbial cells are detectable. In one embodiment, substantially free of residual habitat products may also mean that the bacterial composition contains no detectable viral (including bacterial viruses (i.e., phage)), fungal, mycoplasmal contaminants.
  • bacterial viruses i.e., phage
  • it means that fewer than 1 x10 "2 %, 1 x10 "3 %, 1x10 "4 %, 1 x10 "5 %, 1 x10 "6 %, 1x10 "7 %, 1 x10 "8 of the viable cells in the bacterial composition are human or animal, as compared to microbial cells.
  • contamination may be reduced by isolating desired constituents through multiple steps of streaking to single colonies on solid media until replicate (such as, but not limited to, two) streaks from serial single colonies have shown only a single colony morphology.
  • reduction of contamination can be accomplished by multiple rounds of serial dilutions to single desired cells (e.g., a dilution of 10 "8 or 10 "9 ), such as through multiple 10-fold serial dilutions. This can further be confirmed by showing that multiple isolated colonies have similar cell shapes and Gram staining behavior.
  • Other methods for confirming adequate purity include genetic analysis (e.g. PCR, DNA sequencing), serology and antigen analysis, enzymatic and metabolic analysis, and methods using instrumentation such as flow cytometry with reagents that distinguish desired constituents from contaminants.
  • Physical tree refers to a graphical representation of the evolutionary relationships of one genetic sequence to another that is generated using a defined set of phylogenetic reconstruction algorithms (e.g. parsimony, maximum likelihood, or
  • Bayesian Nodes in the tree represent distinct ancestral sequences and the confidence of any node is provided by a bootstrap or Bayesian posterior probability, which measures branch uncertainty.
  • Operational taxonomic unit refers to a terminal leaf in a phylogenetic tree and is defined by a specific genetic sequence and all sequences that share sequence identity to this sequence at the level of species.
  • a "type” or a plurality of “types” of bacteria includes an OTU or a plurality of different OTUs, and also encompasses a strain, species, genus, family or order of bacteria.
  • the specific genetic sequence may be the 16S sequence or a portion of the 16S sequence or it may be a functionally conserved housekeeping gene found broadly across the eubacterial kingdom.
  • OTUs share at least 95%, 96%, 97%, 98%, or 99% sequence identity.
  • OTUs are frequently defined by comparing sequences between organisms. Sequences with less than 95% sequence identity are not considered to form part of the same OTU.
  • Clade refers to the set of OTUs or members of a phylogenetic tree downstream of a statistically valid node in a phylogenetic tree.
  • the clade comprises a set of terminal leaves in the phylogenetic tree that is a distinct monophyletic evolutionary unit.
  • 16S sequencing or “16S rRNA” or “16S-rRNA” or “16S” refers to sequence derived by characterizing the nucleotides that comprise the 16S ribosomal RNA gene(s).
  • the bacterial 16S rDNA is approximately 1500 nucleotides in length and is used in reconstructing the evolutionary relationships and sequence similarity of one bacterial isolate to another using phylogenetic approaches.
  • 16S sequences are used for phylogenetic reconstruction as they are in general highly conserved, but contain specific hypervariable regions that harbor sufficient nucleotide diversity to differentiate genera and species of most bacteria, as well as fungi.
  • V1 -V9 regions of the 16S rRNA refers to the first through ninth hypervariable regions of the 16S rRNA gene that are used for genetic typing of bacterial samples. These regions in bacteria are defined by nucleotides 69-99, 137-242, 433-497, 576-682, 822-879, 986-1043, 1 1 17-1 173, 1243-1294 and 1435-1465 respectively using numbering based on the E. coli system of nomenclature. Brosius et al., Complete nucleotide sequence of a 16S ribosomal RNA gene from Escherichia coli, PNAS
  • V1 , V2, V3, V4, V5, V6, V7, V8, and V9 regions are used to characterize an OTU.
  • the V1 , V2, and V3 regions are used to characterize an OTU.
  • the V3, V4, and V5 regions are used to characterize an OTU.
  • the V4 region is used to characterize an OTU.
  • subject refers to any animal subject including humans, laboratory animals (e.g., primates, rats, mice), livestock (e.g., cows, sheep, goats, pigs, turkeys, chickens), and household pets (e.g., dogs, cats, rodents, etc.).
  • the subject or patient may be healthy, or may be suffering from an infection due to a gastrointestinal pathogen or may be at risk of developing or transmitting to others an infection due to a gastrointestinal pathogen.
  • pathobiont refers to specific bacterial species found in healthy hosts that may trigger immune-mediated pathology and/or disease in response to certain genetic or environmental factors. Chow et al., (201 1 ) Curr Op Immunol. Pathobionts of the intestinal microbiota and inflammatory disease. 23: 473-80. Thus, a pathobiont is a pathogen that is mechanistically distinct from an acquired infectious organism. Thus, the term “pathogen” includes both acquired infectious organisms and pathobionts.
  • bacteria and combinations of bacteria of the human gut microbiota with the capacity to meaningfully provide functions of a healthy microbiota or catalyze an augmentation to the resident microbiome when administered to mammalian hosts.
  • synergistic combinations that treat, prevent, delay or reduce the symptoms of diseases, disorders and conditions associated with a dysbiosis.
  • Representative diseases, disorders and conditions potentially associated with a dysbiosis which are suitable for treatment with the compositions and methods as described herein, are provided in Tables 8 and 9.
  • compositions inhibit the growth, proliferation, and/or colonization of one or a plurality of pathogenic bacteria in the dysbiotic microbiotal niche, so that a healthy, diverse and protective microbiota colonizes and populates the intestinal lumen to establish or reestablish ecological control over pathogens or potential pathogens (e.g., some bacteria are pathogenic bacteria only when present in a dysbiotic environment).
  • pathogens include those pathogens such as C. difficile, Salmonella spp., enteropathogenic E coli, multi-drug resistant bacteria such as
  • VRE Enterococci
  • Bacterial compositions may comprise two types of bacteria (termed “binary combinations” or “binary pairs”) or greater than two types of bacteria. Bacterial compositions that comprise three types of bacteria are termed "ternary combinations". For instance, a bacterial composition may comprise at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 1 1 , at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, or at least 21 , 22, 23, 24, 25, 26, 27, 28, 29 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, or at least 40, at least 50 or greater than 50 types of bacteria, as defined by species or operational taxonomic unit (OTU), or otherwise as provided herein. In one embodiment, the composition comprises at least two types of bacteria chosen from Table 1 .
  • the number of types of bacteria present in a bacterial composition is at or below a known value.
  • the bacterial composition comprises 50 or fewer types of bacteria, such as 49, 48, 47, 46, 45, 44, 43, 42, 41 , 40, 39, 38, 37, 36, 35, 34, 33, 32, 31 , 30, 29, 28, 27, 26, 25, 24, 23, 22, 21 , 20, 19, 18, 17, 16, 15, 14, 13, 12, 1 1 , or 10 or fewer, or 9 or fewer types of bacteria, 8 or fewer types of bacteria, 7 or fewer types of bacteria, 6 or fewer types of bacteria, 5 or fewer types of bacteria, 4 or fewer types of bacteria, or 3 or fewer types of bacteria.
  • a bacterial composition comprises from 2 to no more than 40, from 2 to no more than 30, from 2 to no more than 20, from 2 to no more than 15, from 2 to no more than 10, or from 2 to no more than 5 types of bacteria.
  • bacterial compositions are provided with the ability to exclude pathogenic bacteria.
  • Exemplary bacterial compositions are demonstrated to reduce the growth rate of one pathogen, C. difficile, as provided in the Examples, wherein the ability of the bacterial compositions is demonstrated by assessing the antagonism activity of a combination of OTUs or strains towards a given pathogen using in vitro assays.
  • bacterial compositions with the capacity to durably exclude C. difficile are developed using a methodology for estimating an Ecological Control Factor (ECF) for constituents within the human microbiota.
  • ECF Ecological Control Factor
  • the ECF is determined by assessing the antagonistic activity of a given commensal strain or combination of strains towards a given pathogen using an in vitro assay, resulting in observed levels of ecological control at various concentrations of the added commensal strains.
  • the ECF for a commensal strain or combination of strains is somewhat analogous to the longstanding minimal inhibitory concentration (MIC) assessment that is employed in the assessment of antibiotics.
  • the ECF allows for the assessment and ranking of relative potencies of commensal strains and combinations of strains for their ability to antagonize gastrointestinal pathogens.
  • the ECF of a commensal strain or combination of strains may be calculated by assessing the concentration of that composition that is able to mediate a given percentage of inhibition (e.g., at least 10%, 20%, 50%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%) of a target pathogen in the in vitro assay.
  • Provided herein are combinations of strains or OTUs within the human microbiota that are able to significantly reduce the rate of gastrointestinal pathogen replication within the in vitro assay. These compositions are capable of providing a safe and effective means by which to affect the growth, replication, and disease severity of such bacterial pathogens.
  • Bacterial compositions may be prepared comprising at least two types of isolated bacteria, wherein a first type and a second type are independently chosen from the species or OTUs listed in Table 1 and Table 3. Certain embodiments of bacterial compositions with at least two types of isolated bacteria containing binary pairs are reflected in Table 2. Additionally, a bacterial composition may be prepared comprising at least two types of isolated bacteria, wherein a first OTU and a second OTU are independently characterized by, i.e., at least 95%, 96%, 97%, 98%, 99% or including 100% sequence identity to, sequences listed in Table 3. Generally, the first bacteria and the second bacteria are not the same OTU. The sequences provided in Table 3 are full 16S sequences.
  • the first and/or second OTUs may be characterized by the full 16S sequences listed in Table 3.
  • the first and/or second OTUs may be characterized by one or more of the variable regions of the 16S sequence (V1 -V9). These regions in bacteria are defined by nucleotides 69- 99, 137-242, 433-497, 576-682, 822-879, 986-1043, 1 1 17-1 173, 1243-1294 and 1435- 1465 respectively using numbering based on the E. coli system of nomenclature.
  • V1 , V2, V3, V4, V5, V6, V7, V8, and V9 regions are used to characterize an OTU.
  • the V1 , V2, and V3 regions are used to characterize an OTU.
  • the V3, V4, and V5 regions are used to characterize an OTU.
  • the V4 region is used to characterize an OTU.
  • OTUs may be defined either by full 16S sequencing of the rRNA gene, by sequencing of a specific hypervariable region of this gene (i.e. V1 , V2, V3, V4, V5, V6, V7, V8, or V9), or by sequencing of any combination of hypervariable regions from this gene (e.g. V1 -3 or V3-5).
  • the bacterial 16S rDNA is approximately 1500 nucleotides in length and is used in reconstructing the evolutionary relationships and sequence similarity of one bacterial isolate to another using phylogenetic approaches. 16S sequences are used for phylogenetic
  • genomic DNA is extracted from a bacterial sample, the 16S rDNA (full region or specific hypervariable regions) amplified using polymerase chain reaction (PCR), the PCR products cleaned, and nucleotide sequences delineated to determine the genetic composition of 16S gene or subdomain of the gene.
  • PCR polymerase chain reaction
  • the sequencing may be, but is not limited to being, performed using the Sanger method or using a next- generation sequencing method, such as an lllumina (sequencing by synthesis) method using barcoded primers allowing for multiplex reactions.
  • a next- generation sequencing method such as an lllumina (sequencing by synthesis) method using barcoded primers allowing for multiplex reactions.
  • Bacterial Compositions exclusive of certain bacterial species or strains. In one embodiment, the bacterial composition does not comprise at least one of
  • Enterococcus faecalis (previously known as Streptococcus faecalis), Clostridium innocuum, Clostridium ramosum, Bacteroides ovatus, Bacteroides vulgatus, Bacteroides thetaoiotaomicron, Escherichia coli (1 109 and 1 108-1 ), Clostridum bifermentans, and Blautia producta (previously known as Peptostreptococcus productus).
  • the bacterial composition does not comprise at least one of Acidaminococcus intestinalis, Bacteroides ovatus, two species of
  • Bifidobacterium adolescentis two species of Bifidobacterium longum, Collinsella aerofaciens, two species of Dorea longicatena, Escherichia coli, Eubacterium eligens, Eubacterium limosum, four species of Eubacterium rectale, Eubacterium ventriosumi, Faecalibacterium prausnitzii, Lactobacillus casei, Lactobacillus paracasei, Paracateroides distasonis, Raoultella sp., one species of Roseburia (chosen from Roseburia faecalis or Roseburia faecis), Roseburia intestinalis, two species of
  • the bacterial composition does not comprise at least one of Barnesiella intestinihominis; Lactobacillus reuteri; a species characterized as one of Enterococcus hirae, Enterococus faecium, or Enterococcus durans; a species characterized as one of Anaerostipes caccae or Clostridium indolis; a species characterized as one of Staphylococcus warneri or Staphylococcus pasteuri; and Adlercreutzia equolifaciens.
  • the bacterial composition does not comprise at least one of Clostridium absonum, Clostridium argentinense, Clostridium baratii, Clostridium bifermentans, Clostridium botulinum, Clostridium butyricum, Clostridium cadaveris, Clostridium camis, Clostridium celatum, Clostridium chauvoei, Clostridium clostridioforme, Clostridium cochlearium, Clostridium difficile, Clostridium fallax, Clostridium felsineum, Clostridium ghonii, Clostridium glycolicum, Clostridium
  • Clostridium haemolyticum Clostridium hastiforme, Clostridium histolyticum, Clostridium indolis, Clostridium innocuum, Clostridium irregulare, Clostridium limosum, Clostridium malenominatum, Clostridium novyi, Clostridium oroticum, Clostridium paraputrificum, Clostridium perfringens, Clostridium piliforme, Clostridium putrefaciens, Clostridium putrificum, Clostridium ramosum, Clostridium sardiniense, Clostridium sartagoforme, Clostridium scindens, Clostridium septicum, Clostridium sordellii, Clostridium
  • Clostridium sphenoides Clostridium spiroforme, Clostridium sporogenes, Clostridium subterminale, Clostridium symbiosum, Clostridium tertium, Clostridium tetani, Clostridium welchii, and Clostridium villosum.
  • the bacterial composition does not comprise at least one of Clostridium innocuum, Clostridum bifermentans, Clostridium butyricum, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, three strains of Escherichia coli, and Lactobacillus sp..
  • the bacterial composition does not comprise at least one of Clostridium bifermentans, Clostridium innocuum, Clostridium butyricum, three strains of Escherichia coli, three strains of Bacteroides, and Blautia producta (previously known as Peptostreptococcus productus).
  • the bacterial composition does not comprise at least one of Bacteroides sp., Escherichia coli, and non pathogenic Clostridia, including Clostridium innocuum, Clostridium bifermentans and Clostridium ramosum.
  • the bacterial composition does not comprise at least one of more than one Bacteroides species, Escherichia coli and non-pathogenic Clostridia, such as Clostridium butyricum, Clostridium bifermentans and Clostridium innocuum.
  • the bacterial composition does not comprise at least one of Bacteroides caccae, Bacteroides capillosus, Bacteroides coagulans, Bacteroides distasonis, Bacteroides eggerthii, Bacteroides forsythus, Bacteroides fragilis, Bacteroides fragilis-ryhm, Bacteroides gracilis, Bacteroides levii, Bacteroides macacae, Bacteroides merdae, Bacteroides ovatus, Bacteroides pneumosintes, Bacteroides putredinis, Bacteroides pyogenes, Bacteroides splanchnicus, Bacteroides stercoris, Bacteroides tectum, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides ureolyticus, and Bacteroides vulgatus.
  • the bacterial composition does not comprise at least one of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, Escherichia coli, Gemmiger, Desulfomonas, and Peptostreptococcus.
  • the bacterial composition does not comprise at least one of Bacteroides fragilis ss. Vulgatus, Eubacterium aerofaciens, Bacteroides fragilis ss. Thetaiotaomicron, Blautia producta (previously known as Peptostreptococcus productus II), Bacteroides fragilis ss. Distasonis, Fusobacterium prausnitzii,
  • Coprococcus eutactus Eubacterium aerofaciens III, Blautia producta (previously known as Peptostreptococcus productus I), Ruminococcus bromii, Bifidobacterium
  • Eubacterium ventriosum Bacteroides fragilis ss. fragilis, Bacteroides AR, Coprococcus catus, Eubacterium hadrum, Eubacterium cylindroides, Eubacterium ruminantium, Eu bacterium CH-1, Staphylococcus epidermidis, Peptostreptococcus BL, Eubacterium limosum, Bacteroides praeacutus, Bacteroides L, Fusobacterium mortiferum I,
  • Propionibacterium acnes Ruminococcus flavefaciens, Ruminococcus AT, Peptococcus AU-1, Eubacterium AG, -AK, -AL, -AL-1, -AN; Bacteroides fragilis ss. ovatus, -ss. d, -ss. f; Bacteroides L-1, L-5; Fusobacterium nucleatum, Fusobacterium mortiferum,
  • Escherichia coli Streptococcus morbiliorum, Peptococcus magnus, Peptococcus G, AU- 2; Streptococcus intermedius, Ruminococcus lactaris, Ruminococcus CO Gemmiger X, Coprococcus BH, -CC; Eubacterium ska, Eubacterium ramulus, Eubacterium AE, - AG-H, -AG-M, -AJ, -BN-1; Bacteroides clostridiiformis ss. clostridliformis, Bacteroides coagulans, Bacteroides orails, Bacteroides ruminicola ss. brevis, -ss. ruminicola,
  • the bacterial compositions offer a protective or therapeutic effect against infection by one or more Gl pathogens of interest.
  • the pathogenic bacterium is selected from the group consisting of Yersinia, Vibrio, Treponema, Streptococcus, Staphylococcus, Shigella, Salmonella, Rickettsia, Orientia, Pseudomonas, Neisseria, Mycoplasma, Mycobacterium, Listeria, Leptospira, Legionella, Klebsiella, Helicobacter, Haemophilus, Francisella, Escherichia, Ehrlichia, Enterococcus, Coxiella, Corynebacterium,
  • CRE Enterobacteriaceae
  • VRE vancomycin-resistant Enterococci
  • these pathogens include, but are not limited to, Aeromonas hydrophila, Campylobacter fetus, Plesiomonas shigelloides, Bacillus cereus, Campylobacter jejuni, Clostridium botulinum, Clostridium difficile, Clostridium
  • enteroaggregative Escherichia coli enterohemorrhagic Escherichia coli, enteroinvasive Escherichia coli, enterotoxigenic Escherichia coli (such as, but not limited to, LT and/or ST), Escherichia coli 0157:H7, Helicobacter pylori, Klebsiellia pneumonia, Lysteria monocytogenes, Plesiomonas shigelloides, Salmonella spp., Salmonella typhi, Salmonella paratyphi, Shigella spp., Staphylococcus spp., Staphylococcus aureus, vancomycin-resistant enterococcus spp., Vibrio spp., Vibrio cholerae, Vibrio
  • the pathogen of interest is at least one pathogen chosen from Clostridium difficile, Salmonella spp., pathogenic Escherichia coli, vancomycin-resistant Enterococcus spp., and extended spectrum beta-lactam resistant Enterococci (ESBL).
  • ESBL extended spectrum beta-lactam resistant Enterococci
  • an In Vitro Assay utilizing competition between the bacterial compositions or subsets thereof and C. difficile. Exemplary embodiments of this Assay are provided herein and in the Examples.
  • an In Vitro Assay utilizing 10% (wt/vol) Sterile-Filtered Feces.
  • an in vitro assay to test for the protective effect of the bacterial compositions and to screen in vitro for combinations of microbes that inhibit the growth of a pathogen.
  • the assay can operate in automated high-throughput or manual modes. Under either system, human or animal feces may be re-suspended in an anaerobic buffer solution, such as pre-reduced PBS or other suitable buffer, the particulate removed by centrifugation, and filter sterilized. This 10% sterile-filtered feces material serves as the base media for the in vitro assay.
  • an investigator may add it to the sterile-filtered feces material for a first incubation period and then may inoculate the incubated microbial solution with the pathogen of interest for a second incubation period.
  • the resulting titer of the pathogen may be quantified by any number of methods such as those described below, and the change in the amount of pathogen is compared to standard controls including the pathogen cultivated in the absence of the bacterial composition.
  • the assay is conducted using at least one control. Feces from a healthy subject may be used as a positive control. As a negative control, antibiotic-treated feces or heat-treated feces may be used.
  • compositions may be tested in this material and the bacterial compositions optionally compared to the positive and/or negative controls.
  • the ability to inhibit the growth of the pathogen may be measured by plating the incubated material on C. difficile selective media and counting colonies. After competition between the bacterial composition and C. difficile, each well of the in vitro assay plate is serially diluted ten-fold six times, and plated on selective media, such as but not limited to cycloserine cefoxitin mannitol agar (CCMA) or cycloserine cefoxitin fructose agar (CCFA), and incubated. Colonies of C. difficile are then counted to calculate the concentration of viable cells in each well at the end of the competition. Colonies of C. difficile are confirmed by their characteristic diffuse colony edge morphology as well as fluorescence under UV light.
  • the in vitro assay utilizes Antibiotic-Treated Feces.
  • human or animal feces may be resuspended in an anaerobic buffer solution, such as pre-reduced PBS or other suitable buffer.
  • the resuspended feces is treated with an antibiotic, such as clindamycin, or a cocktail of several antibiotics in order to reduce the ability of feces from a healthy subject to inhibit the growth of C. difficile; this material is termed the antibiotic-treated matrix. While not being bound by any mechanism, it is believed that beneficial bacteria in healthy subjects protects them from infection by competing out C. difficile.
  • Antibiotics in addition to clindamycin that inhibit the normal flora include ceftriaxone and piperacillin-tazobactam and may be substituted for the clindamycin.
  • the antibiotic-treated matrix is centrifuged, the supernatant removed, and the pelleted material resuspended in filter-sterilized, diluted feces in order to remove any residual antibiotic. This washed antibiotic-treated matrix may be used in the in vitro assay described above in lieu of the 10% sterile- filtered feces.
  • the ability to inhibit the growth of the pathogen may be measured by quantitative PCR (qPCR). Standard techniques may be followed to generate a standard curve for the pathogen of interest.
  • Genomic DNA may be extracted from samples using commercially-available kits, such as the Mo Bio Powersoil®-htp 96 Well Soil DNA Isolation Kit (Mo Bio Laboratories, Carlsbad, CA), the Mo Bio Powersoil® DNA Isolation Kit (Mo Bio Laboratories, Carlsbad, CA), or the QIAamp DNA Stool Mini Kit (QIAGEN, Valencia, CA) according to the manufacturer's instructions.
  • the qPCR may be conducted using HotMasterMix (5PRIME, Gaithersburg, MD) and primers specific for the pathogen of interest, and may be conducted on a MicroAmp ® Fast Optical 96-well Reaction Plate with Barcode (0.1 mL) (Life Technologies, Grand Island, NY) and performed on a BioRad C1000TM Thermal Cycler equipped with a CFX96TM Real-Time System (BioRad, Hercules, CA), with fluorescent readings of the FAM and ROX channels.
  • the Cq value for each well on the FAM channel is determined by the CFX ManagerTM software version 2.1 .
  • the logio(cfu/ml) of each experimental sample is calculated by inputting a given sample's Cq value into linear regression model generated from the standard curve comparing the Cq values of the standard curve wells to the known logio(cfu/ml) of those samples.
  • the skilled artisan may employ alternative qPCR modes.
  • mice are made susceptible to C.
  • Bacterial compositions may be given either before or after a 7 day treatment (days -12 to -5 of experiment) with 5 to 7 antibiotics (including kanamycin, colistin, gentamycin, metronidazole and vancomycin and optionally including ampicillin and ciprofloxacin) delivered via their drinking water, followed by a single dose with Clindamycin on day -3, then challenged three days later on day 0 with 10 4 spores of C. difficile via oral gavage (i.e., oro-gastric lavage).
  • Bacterial compositions may be given either before
  • bacterial compositions may be given after (optional) vancomycin treatment (see below) to assess their ability to prevent recurrence and thus suppress the pathogen in vivo.
  • the outcomes assessed each day from day -1 to day 6 (or beyond, for prevention of recurrence) are weight, clinical signs, mortality and shedding of C. difficile in the feces. Weight loss, clinical signs of disease, and C. difficile shedding are typically observed without treatment.
  • Vancomycin provided by oral gavage on days -1 to 4 protects against these outcomes and serves as a positive control. Clinical signs are subjective, and scored each day by the same experienced observer.
  • Feces Animals that lose greater than or equal to 25% of their body weight are euthanized and counted as infection-related mortalities. Feces are gathered from mouse cages (5 mice per cage) each day, and the shedding of C. difficile spores is detected in the feces using a selective plating assay as described for the in vitro assay above, or via qPCR for the toxin gene as described herein.
  • test materials including 10% suspension of human feces (as a positive control), bacterial compositions, or PBS (as a negative vehicle control), are determined by introducing the test article in a 0.2 ml_ volume into the mice via oral gavage on day -1 , one day prior to C.
  • Vancomycin as discussed above, is given on days 1 to 4 as another positive control.
  • Alternative dosing schedules and routes of administration may be employed, including multiple doses of test article, and 10 3 to 10 10 of a given organism or composition may be delivered.
  • Methods for producing bacterial compositions may include three main processing steps, combined with one or more mixing steps. The steps are: organism banking, organism production, and preservation.
  • the strains included in the bacterial composition may be (1 ) isolated directly from a specimen or taken from a banked stock, (2) optionally cultured on a nutrient agar or broth that supports growth to generate viable biomass, and (3) the biomass optionally preserved in multiple aliquots in long-term storage.
  • the agar or broth may contain nutrients that provide essential elements and specific factors that enable growth.
  • An example would be a medium composed of 20 g/L glucose, 10 g/L yeast extract, 10 g/L soy peptone, 2 g/L citric acid, 1 .5 g/L sodium phosphate monobasic, 100 mg/L ferric ammonium citrate, 80 mg/L magnesium sulfate, 10 mg/L hemin chloride, 2 mg/L calcium chloride, 1 mg/L menadione.
  • a variety of microbiological media and variations are well known in the art (e.g. R.M. Atlas, Handbook of Microbiological Media (2010) CRC Press).
  • Medium can be added to the culture at the start, may be added during the culture, or may be intermittently/continuously flowed through the culture.
  • the strains in the bacterial composition may be cultivated alone, as a subset of the bacterial composition, or as an entire collection comprising the bacterial composition.
  • a first strain may be cultivated together with a second strain in a mixed continuous culture, at a dilution rate lower than the maximum growth rate of either cell to prevent the culture from washing out of the cultivation.
  • the inoculated culture is incubated under favorable conditions for a time sufficient to build biomass.
  • bacterial compositions for human use this is often at 37°C temperature, pH, and other parameter with values similar to the normal human niche.
  • the environment may be actively controlled, passively controlled (e.g., via buffers), or allowed to drift.
  • anaerobic bacterial compositions e.g., gut microbiota
  • an anoxic/reducing environment may be employed. This can be
  • reducing agents such as cysteine
  • a culture of a bacterial composition may be grown at 37°C, pH 7, in the medium above, pre-reduced with 1 g/L cysteine e HCI.
  • the culture When the culture has generated sufficient biomass, it may be preserved for banking.
  • the organisms may be placed into a chemical milieu that protects from freezing (adding 'cryoprotectants'), drying ('lyoprotectants'), and/or osmotic shock ('osmoprotectants'), dispensing into multiple (optionally identical) containers to create a uniform bank, and then treating the culture for preservation.
  • Containers are generally impermeable and have closures that assure isolation from the environment.
  • Cryopreservation treatment is accomplished by freezing a liquid at ultra-low
  • Dried preservation removes water from the culture by evaporation (in the case of spray drying or 'cool drying') or by sublimation (e.g., for freeze drying, spray freeze drying). Removal of water improves long-term bacterial composition storage stability at temperatures elevated above cryogenic. If the bacterial composition comprises spore forming species and results in the production of spores, the final composition may be purified by additional means such as density gradient centrifugation preserved using the techniques described above. Bacterial composition banking may be done by culturing and preserving the strains individually, or by mixing the strains together to create a combined bank. As an example of
  • a bacterial composition culture may be harvested by centrifugation to pellet the cells from the culture medium, the supernate decanted and replaced with fresh culture broth containing 15% glycerol. The culture can then be aliquoted into 1 ml_ cryotubes, sealed, and placed at -80°C for long-term viability retention. This procedure achieves acceptable viability upon recovery from frozen storage.
  • Organism production may be conducted using similar culture steps to banking, including medium composition and culture conditions. It may be conducted at larger scales of operation, especially for clinical development or commercial production. At larger scales, there may be several subcultivations of the bacterial composition prior to the final cultivation. At the end of cultivation, the culture is harvested to enable further formulation into a dosage form for administration. This can involve concentration, removal of undesirable medium components, and/or introduction into a chemical milieu that preserves the bacterial composition and renders it acceptable for administration via the chosen route. For example, a bacterial composition may be cultivated to a
  • the spent medium may be exchanged by diafiltering with a preservative medium consisting of 2% gelatin, 100 mM trehalose, and 10 mM sodium phosphate buffer.
  • a preservative medium consisting of 2% gelatin, 100 mM trehalose, and 10 mM sodium phosphate buffer.
  • the suspension can then be freeze-dried to a powder and titrated.
  • the powder may be blended to an appropriate potency, and mixed with other cultures and/or a filler such as microcrystalline cellulose for consistency and ease of handling, and the bacterial composition formulated as provided herein.
  • a filler such as microcrystalline cellulose for consistency and ease of handling, and the bacterial composition formulated as provided herein.
  • Formulations Provided are formulations for administration to humans and other subjects in need thereof. Generally the bacterial compositions are combined with additional active and/or inactive materials in order to produce a final product, which may be in single dosage unit or in a multi-dose format.
  • composition comprises at least one
  • a “carbohydrate” refers to a sugar or polymer of sugars.
  • saccharide The terms “saccharide,” “polysaccharide,” “carbohydrate,” and “oligosaccharide” may be used interchangeably.
  • Most carbohydrates are aldehydes or ketones with many hydroxyl groups, usually one on each carbon atom of the molecule. Carbohydrates generally have the molecular formula C n H2nO n .
  • a carbohydrate may be a monosaccharide, a disaccharide, trisaccharide, oligosaccharide, or polysaccharide.
  • the most basic carbohydrate is a monosaccharide, such as glucose, sucrose, galactose, mannose, ribose, arabinose, xylose, and fructose. Disaccharides are two joined
  • oligosaccharide includes between three and six monosaccharide units (e.g., raffinose, stachyose), and polysaccharides include six or more
  • Carbohydrates may contain modified saccharide units such as 2'-deoxyribose wherein a hydroxyl group is removed, 2'-fluororibose wherein a hydroxyl group is replace with a fluorine, or N-acetylglucosamine, a nitrogen-containing form of glucose (e.g., 2'-fluororibose, deoxyribose, and hexose).
  • Carbohydrates may exist in many different forms, for example, conformers, cyclic forms, acyclic forms, stereoisomers, tautomers, anomers, and isomers.
  • the composition comprises at least one lipid.
  • a lipid includes fats, oils, triglycerides, cholesterol, phospholipids, fatty acids in any form including free fatty acids. Fats, oils and fatty acids can be saturated, unsaturated (cis or trans) or partially unsaturated (cis or trans).
  • the lipid comprises at least one fatty acid selected from lauric acid (12:0), myristic acid (14:0), palmitic acid (16:0), palmitoleic acid (16:1 ), margaric acid (17:0), heptadecenoic acid (17:1 ), stearic acid (18:0), oleic acid (18:1 ), linoleic acid (18:2), linolenic acid (18:3), octadecatetraenoic acid (18:4), arachidic acid (20:0), eicosenoic acid (20:1 ),
  • the composition comprises at least one modified lipid, for example a lipid that has been modified by cooking.
  • composition comprises at least one
  • supplemental mineral or mineral source examples include, without limitation: chloride, sodium, calcium, iron, chromium, copper, iodine, zinc, magnesium, manganese, molybdenum, phosphorus, potassium, and selenium.
  • Suitable forms of any of the foregoing minerals include soluble mineral salts, slightly soluble mineral salts, insoluble mineral salts, chelated minerals, mineral complexes, non-reactive minerals such as carbonyl minerals, and reduced minerals, and combinations thereof.
  • composition comprises at least one
  • the at least one vitamin can be fat-soluble or water soluble vitamins.
  • Suitable vitamins include but are not limited to vitamin C, vitamin A, vitamin E, vitamin B12, vitamin K, riboflavin, niacin, vitamin D, vitamin B6, folic acid, pyridoxine, thiamine, pantothenic acid, and biotin.
  • Suitable forms of any of the foregoing are salts of the vitamin, derivatives of the vitamin, compounds having the same or similar activity of the vitamin, and metabolites of the vitamin.
  • the composition comprises an excipient.
  • excipients include a buffering agent, a preservative, a stabilizer, a binder, a compaction agent, a lubricant, a dispersion enhancer, a
  • disintegration agent a flavoring agent, a sweetener, and a coloring agent.
  • the excipient is a buffering agent.
  • suitable buffering agents include sodium citrate, magnesium carbonate, magnesium bicarbonate, calcium carbonate, and calcium bicarbonate.
  • the excipient comprises a preservative.
  • suitable preservatives include antioxidants, such as alpha- tocopherol and ascorbate, and antimicrobials, such as parabens, chlorobutanol, and phenol.
  • the composition comprises a binder as an excipient.
  • suitable binders include starches, pregelatinized starches, gelatin, polyvinylpyrolidone, cellulose, methylcellulose, sodium carboxymethylcellulose, ethylcellulose, polyacrylamides, polyvinyloxoazolidone, polyvinylalcohols, C12-C18 fatty acid alcohol, polyethylene glycol, polyols, saccharides, oligosaccharides, and combinations thereof.
  • the composition comprises a lubricant as an excipient.
  • suitable lubricants include magnesium stearate, calcium stearate, zinc stearate, hydrogenated vegetable oils, sterotex, polyoxyethylene monostearate, talc, polyethyleneglycol, sodium benzoate, sodium lauryl sulfate, magnesium lauryl sulfate, and light mineral oil.
  • the composition comprises a dispersion enhancer as an excipient.
  • suitable dispersants include starch, alginic acid, polyvinylpyrrolidones, guar gum, kaolin, bentonite, purified wood cellulose, sodium starch glycolate, isoamorphous silicate, and microcrystalline cellulose as high HLB emulsifier surfactants.
  • the composition comprises a disintegrant as an excipient.
  • the disintegrant is a non-effervescent disintegrant.
  • suitable non-effervescent disintegrants include starches such as corn starch, potato starch, pregelatinized and modified starches thereof, sweeteners, clays, such as bentonite, micro-crystalline cellulose, alginates, sodium starch glycolate, gums such as agar, guar, locust bean, karaya, pecitin, and tragacanth.
  • the disintegrant is an effervescent disintegrant.
  • suitable effervescent disintegrants include sodium bicarbonate in combination with citric acid, and sodium bicarbonate in combination with tartaric acid.
  • the excipient comprises a flavoring agent.
  • Flavoring agents can be chosen from synthetic flavor oils and flavoring aromatics
  • the flavoring agent is selected from cinnamon oils; oil of wintergreen; peppermint oils; clover oil; hay oil; anise oil; eucalyptus; vanilla; citrus oil such as lemon oil, orange oil, grape and grapefruit oil; and fruit essences including apple, peach, pear, strawberry, raspberry, cherry, plum, pineapple, and apricot.
  • the excipient comprises a sweetener.
  • suitable sweeteners include glucose (corn syrup), dextrose, invert sugar, fructose, and mixtures thereof (when not used as a carrier); saccharin and its various salts such as the sodium salt; dipeptide sweeteners such as aspartame;
  • dihydrochalcone compounds glycyrrhizin; Stevia Rebaudiana (Stevioside); chloro derivatives of sucrose such as sucralose; and sugar alcohols such as sorbitol, mannitol, sylitol, and the like.
  • hydrogenated starch hydrolysates and the synthetic sweetener 3,6-dihydro-6-methyl-1 ,2,3-oxathiazin-4-one-2,2-dioxide particularly the potassium salt (acesulfame-K), and sodium and calcium salts thereof.
  • the composition comprises a coloring agent.
  • suitable color agents include food, drug and cosmetic colors (FD&C), drug and cosmetic colors (D&C), and external drug and cosmetic colors (Ext. D&C).
  • the coloring agents can be used as dyes or their corresponding lakes.
  • the weight fraction of the excipient or combination of excipients in the formulation is usually about 99% or less, such as about 95% or less, about 90% or less, about 85% or less, about 80% or less, about 75% or less, about 70% or less, about 65% or less, about 60% or less, about 55% or less, 50% or less, about 45% or less, about 40% or less, about 35% or less, about 30% or less, about 25% or less, about 20% or less, about 15% or less, about 10% or less, about 5% or less, about 2% or less, or about 1 % or less of the total weight of the composition.
  • compositions disclosed herein can be formulated into a variety of forms and administered by a number of different means.
  • the compositions can be administered orally, rectally, or parenterally, in formulations containing
  • the bacterial composition is administered orally.
  • Solid dosage forms for oral administration include capsules, tablets, caplets, pills, troches, lozenges, powders, and granules.
  • a capsule typically comprises a core material comprising a bacterial composition and a shell wall that encapsulates the core material.
  • the core material comprises at least one of a solid, a liquid, and an emulsion.
  • the shell wall material comprises at least one of a soft gelatin, a hard gelatin, and a polymer.
  • Suitable polymers include, but are not limited to: cellulosic polymers such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose (HPMC), methyl cellulose, ethyl cellulose, cellulose acetate, cellulose acetate phthalate, cellulose acetate trimellitate,
  • acrylic acid polymers and copolymers such as those formed from acrylic acid, methacrylic acid, methyl acrylate, ammonio methylacrylate, ethyl acrylate, methyl methacrylate and/or ethyl methacrylate (e.g., those copolymers sold under the trade name "Eudragit”); vinyl polymers and copolymers such as polyvinyl pyrrolidone, polyvinyl acetate, polyvinylacetate phthalate, vinylacetate crotonic acid copolymer, and ethylene-vinyl acetate copolymers; and shellac (purified lac).
  • at least one polymer functions as taste-masking agents.
  • Tablets, pills, and the like can be compressed, multiply compressed, multiply layered, and/or coated.
  • the coating can be single or multiple. In one
  • the coating material comprises at least one of a saccharide, a
  • Non-limiting examples include corn starch, wheat starch, potato starch, tapioca starch, cellulose, hemicellulose, dextrans, maltodextrin, cyclodextrins, inulins, pectin, mannans, gum arabic, locust bean gum, mesquite gum, guar gum, gum karaya, gum ghatti, tragacanth gum, funori, carrageenans, agar, alginates, chitosans, or gellan gum.
  • the coating material comprises a protein.
  • the coating material comprises at least one of a fat and an oil. In some embodiments the at least one of a fat and an oil is high temperature melting. In some embodiments the at least one of a fat and an oil is hydrogenated or partially hydrogenated. In some embodiments the at least one of a fat and an oil is derived from a plant. In some embodiments the at least one of a fat and an oil comprises at least one of glycerides, free fatty acids, and fatty acid esters. In some embodiments the coating material comprises at least one edible wax. The edible wax can be derived from animals, insects, or plants. Non-limiting examples include beeswax, lanolin, bayberry wax, carnauba wax, and rice bran wax. Tablets and pills can additionally be prepared with enteric coatings.
  • powders or granules embodying the bacterial compositions disclosed herein can be incorporated into a food product.
  • the food product is a drink for oral administration.
  • suitable drink include fruit juice, a fruit drink, an artificially flavored drink, an artificially sweetened drink, a carbonated beverage, a sports drink, a liquid diary product, a shake, an alcoholic beverage, a caffeinated beverage, infant formula and so forth.
  • suitable means for oral administration include aqueous and nonaqueous solutions, emulsions, suspensions and solutions and/or suspensions reconstituted from non-effervescent granules, containing at least one of suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, coloring agents, and flavoring agents.
  • the food product is a solid foodstuff. Suitable examples of a solid foodstuff include without limitation a food bar, a snack bar, a cookie, a brownie, a muffin, a cracker, an ice cream bar, a frozen yogurt bar, and the like.
  • compositions disclosed herein are incorporated into a therapeutic food.
  • the therapeutic food is a ready-to-use food that optionally contains some or all essential macronutrients and micronutrients.
  • the compositions disclosed herein are incorporated into a
  • the supplemental food contains some or all essential macronutrients and micronutrients.
  • the bacterial compositions disclosed herein are blended with or added to an existing food to fortify the food's protein nutrition. Examples include food staples (grain, salt, sugar, cooking oil, margarine), beverages (coffee, tea, soda, beer, liquor, sports drinks), snacks, sweets and other foods.
  • the formulations are filled into gelatin capsules for oral administration.
  • An example of an appropriate capsule is a 250 mg gelatin capsule containing from 10 (up to 100 mg) of lyophilized powder (10 8 to 10 11 bacteria), 160 mg microcrystalline cellulose, 77.5 mg gelatin, and 2.5 mg magnesium stearate.
  • from 10 5 to 10 12 bacteria may be used, 10 5 to 10 7 , 10 6 to 10 7 , or 10 8 to 10 10 , with attendant adjustments of the excipients if necessary.
  • an enteric-coated capsule or tablet or with a buffering or protective composition may be used.
  • the number of bacteria of each type may be present in the same amount or in different amounts.
  • the bacteria in a bacterial composition with two types of bacteria, the bacteria may be present in from a 1 :10,000 ratio to a 1 :1 ratio, from a 1 : 10,000 ratio to a 1 : 1 ,000 ratio, from a 1 : 1 ,000 ratio to a 1 : 100 ratio, from a 1 :100 ratio to a 1 :50 ratio, from a 1 :50 ratio to a 1 :20 ratio, from a 1 :20 ratio to a 1 :10 ratio, from a 1 :10 ratio to a 1 :1 ratio.
  • the ratio of type of bacteria may be chosen pairwise from ratios for bacterial compositions with two types of bacteria. For example, in a bacterial
  • composition comprising bacteria A, B, and C, at least one of the ratio between bacteria A and B, the ratio between bacteria B and C, and the ratio between bacteria A and C may be chosen, independently, from the pairwise combinations above.
  • administer and “administration” encompasses embodiments in which one person directs another to consume a bacterial composition in a certain manner and/or for a certain purpose, and also situations in which a user uses a bacteria composition in a certain manner and/or for a certain purpose independently of or in variance to any instructions received from a second person.
  • Non-limiting examples of embodiments in which one person directs another to consume a bacterial composition in a certain manner and/or for a certain purpose include when a physician prescribes a course of conduct and/or treatment to a patient, when a parent commands a minor user (such as a child) to consume a bacterial composition, when a trainer advises a user (such as an athlete) to follow a particular course of conduct and/or treatment, and when a manufacturer, distributer, or marketer recommends conditions of use to an end user, for example through advertisements or labeling on packaging or on other materials provided in association with the sale or marketing of a product.
  • the bacterial compositions offer a protective and/or therapeutic effect against infection by one or more Gl pathogens of interest and thus may be administered after an acute case of infection has been resolved in order to prevent relapse, during an acute case of infection as a complement to antibiotic therapy if the bacterial composition is not sensitive to the same antibiotics as the Gl pathogen, or to prevent infection or reduce transmission from disease carriers.
  • pathogens include, but are not limited to, Aeromonas hydrophila, Campylobacter fetus, Plesiomonas shigelloides, Bacillus cereus, Campylobacter jejuni, Clostridium botulinum, Clostridium difficile, Clostridium perfringens, enteroaggregative Escherichia coli, enterohemorrhagic Escherichia coli, enteroinvasive Escherichia coli, enterotoxigenic Escherichia coli (LT and/or ST),
  • Escherichia coli 0157 H7, Helicobacter pylori, Klebsiella pneumonia, Lysteria
  • Enterococcus spp. Vibrio spp., Vibrio cholerae, Vibrio parahaemolyticus, Vibrio vulnificus, and Yersinia enterocolitica.
  • the pathogen may be Clostridium difficile, Salmonella spp., pathogenic Escherichia coli, Carbapenem-resistent Enterobacteriaceae (CRE), extended spectrum beta-lactam resistant Enterococci (ESBL) and vancomycin-resistant Enterococci (VRE).
  • the pathogen may be Clostridium difficile.
  • the present bacterial compositions may be useful in a variety of clinical situations. For example, the bacterial compositions may be administered as a
  • the present bacterial compositions may be administered to animals, including humans, laboratory animals (e.g., primates, rats, mice), livestock (e.g., cows, sheep, goats, pigs, turkeys, chickens), and household pets (e.g., dogs, cats, rodents).
  • laboratory animals e.g., primates, rats, mice
  • livestock e.g., cows, sheep, goats, pigs, turkeys, chickens
  • household pets e.g., dogs, cats, rodents.
  • the bacterial composition is administered enterically, in other words by a route of access to the gastrointestinal tract.
  • colonoscopy by an oral or nasal tube (nasogastric, nasojejunal, oral gastric, or oral jejunal), as detailed more fully herein.
  • the patient may optionally have a pretreatment protocol to prepare the gastrointestinal tract to receive the bacterial composition.
  • the pretreatment protocol is advisable, such as when a patient has an acute infection with a highly resilient pathogen.
  • the pretreatment protocol is entirely optional, such as when the pathogen causing the infection is not resilient, or the patient has had an acute infection that has been successfully treated but where the physician is concerned that the infection may recur.
  • the pretreatment protocol may enhance the ability of the bacterial composition to affect the patient's microbiome.
  • At least one antibiotic may be administered to alter the bacteria in the patient.
  • a standard colon-cleansing preparation may be administered to the patient to substantially empty the contents of the colon, such as used to prepare a patient for a colonscopy.
  • substantially emptying the contents of the colon this application means removing at least 75%, at least 80%, at least 90%, at least 95%, or about 100% of the contents of the ordinary volume of colon contents.
  • Antibiotic treatment may precede the colon-cleansing protocol.
  • the antibiotic should be stopped in sufficient time to allow the antibiotic to be substantially reduced in concentration in the gut before the bacterial composition is administered.
  • the antibiotic may be discontinued 1 , 2, or 3 days before the administration of the bacterial composition.
  • the antibiotic may be discontinued 3, 4, 5, 6, or 7 antibiotic half-lives before administration of the bacterial composition.
  • the antibiotic may be chosen so the constituents in the bacterial composition have an MIC50 that is higher than the concentration of the antibiotic in the gut.
  • MIC50 of a bacterial composition or the elements in the composition may be determined by methods well known in the art. Reller et al., Antimicrobial
  • the additional time between antibiotic administration and administration of the bacterial composition is not necessary. If the pretreatment protocol is part of treatment of an acute infection, the antibiotic may be chosen so that the infection is sensitive to the antibiotic, but the constituents in the bacterial composition are not sensitive to the antibiotic.
  • the bacterial compositions of the invention are suitable for administration to mammals and non-mammalian animals in need thereof.
  • the mammalian subject is a human subject who has one or more symptoms of a dysbiosis.
  • the bacterial compositions described herein are suitable for treatment thereof.
  • the mammalian subject has not received antibiotics in advance of treatment with the bacterial compositions.
  • the mammalian subject has not been administered at least two doses of vancomycin, metronidazole and/or or similar antibiotic compound within one week prior to administration of the therapeutic composition.
  • the mammalian subject has not previously received an antibiotic compound in the one month prior to administration of the therapeutic composition.
  • the mammalian subject has received one or more treatments with one or more different antibiotic compounds and such treatment(s) resulted in no improvement or a worsening of symptoms.
  • the gastrointestinal disease, disorder or condition is diarrhea caused by C. difficile including recurrent C. difficile infection, ulcerative colitis, colitis, Crohn's disease, or irritable bowel disease.
  • the therapeutic composition is administered only once prior to improvement of the disease, disorder or condition.
  • the therapeutic composition is administered at intervals greater than two days, such as once every three, four, five or six days, or every week or less frequently than every week.
  • the preparation may be administered intermittently according to a set schedule, e.g., once a day, once weekly, or once monthly, or when the subject relapses from the primary illness.
  • the preparation may be administered on a long-term basis to subjects who are at risk for infection with or who may be carriers of these pathogens, including subjects who will have an invasive medical procedure (such as surgery), who will be hospitalized, who live in a long-term care or rehabilitation facility, who are exposed to pathogens by virtue of their profession (livestock and animal processing workers), or who could be carriers of pathogens (including hospital workers such as physicians, nurses, and other health care
  • the bacterial composition is administered enterically.
  • an oral or nasal tube including nasogastric, nasojejunal, oral gastric, or oral jejunal.
  • administration includes rectal administration (including enema, suppository, or colonoscopy).
  • the bacterial composition may be administered to at least one region of the gastrointestinal tract, including the mouth, esophagus, stomach, small intestine, large intestine, and rectum. In some embodiments it is administered to all regions of the gastrointestinal tract.
  • the bacterial compositions may be administered orally in the form of medicaments such as powders, capsules, tablets, gels or liquids.
  • the bacterial compositions may also be administered in gel or liquid form by the oral route or through a nasogastric tube, or by the rectal route in a gel or liquid form, by enema or instillation through a colonoscope or by a suppository.
  • the composition is administered colonoscopically and, optionally, if the bacterial composition is administered by other rectal routes (such as an enema or suppository) or even if the subject has an oral administration, the subject may have a colon-cleansing preparation.
  • the colon-cleansing preparation can facilitate proper use of the colonoscope or other administration devices, but even when it does not serve a mechanical purpose it can also maximize the proportion of the bacterial composition relative to the other organisms previously residing in the gastrointestinal tract of the subject. Any ordinarily acceptable colon-cleansing preparation may be used such as those typically provided when a subject undergoes a colonoscopy.
  • the bacteria and bacterial compositions are provided in a dosage form.
  • the dosage form is designed for administration of at least one OTU or combination thereof disclosed herein, wherein the total amount of bacterial composition administered is selected from 0.1 ng to 10g, 10ng to 1g, 100ng to 0.1g, 0.1 mg to 500mg, 1 mg to 100mg, or from 10-15mg.
  • the bacterial composition is consumed at a rate of from 0.1 ng to 10g a day, 10ng to 1 g a day, 100ng to 0.1 g a day, 0.1 mg to 500mg a day, 1 mg to 100mg a day, or from 10-15mg a day, or more.
  • the treatment period is at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, or at least 1 year.
  • the treatment period is from 1 day to 1 week, from 1 week to 4 weeks, from 1 month, to 3 months, from 3 months to 6 months, from 6 months to 1 year, or for over a year.
  • from 10 5 and 10 12 microorganisms total may be administered to the patient in a given dosage form.
  • an effective amount may be provided in from 1 to 500 ml or from 1 to 500 grams of the bacterial composition having from 10 7 to 10 1 1 bacteria per ml or per gram, or a capsule, tablet or suppository having from 1 mg to 1000 mg lyophilized powder having from 10 7 to 10 11 bacteria.
  • Those receiving acute treatment may receive higher doses than those who are receiving chronic administration (such as hospital workers or those admitted into long-term care facilities).
  • any of the preparations described herein may be administered once on a single occasion or on multiple occasions, such as once a day for several days or more than once a day on the day of administration (including twice daily, three times daily, or up to five times daily). Or the preparation may be administered intermittently according to a set schedule, e.g., once weekly, once monthly, or when the patient relapses from the primary illness.
  • the preparation may be administered on a long-term basis to individuals who are at risk for infection with or who may be carriers of these pathogens, including individuals who will have an invasive medical procedure (such as surgery), who will be hospitalized, who live in a long-term care or rehabilitation facility, who are exposed to pathogens by virtue of their profession (livestock and animal processing workers), or who could be carriers of pathogens (including hospital workers such as physicians, nurses, and other health care professionals).
  • individuals who will have an invasive medical procedure such as surgery
  • who will be hospitalized who live in a long-term care or rehabilitation facility, who are exposed to pathogens by virtue of their profession (livestock and animal processing workers), or who could be carriers of pathogens (including hospital workers such as physicians, nurses, and other health care professionals).
  • Particular bacterial compositions may be selected for individual patients or for patients with particular profiles.
  • 16S sequencing may be performed for a given patient to identify the bacteria present in his or her microbiota.
  • the sequencing may either profile the patient's entire microbiome using 16S sequencing (to the family, genera, or species level), a portion of the patient's microbiome using 16S sequencing, or it may be used to detect the presence or absence of specific candidate bacteria that are biomarkers for health or a particular disease state, such as markers of multi-drug resistant organisms or specific genera of concern such as Escherichia.
  • a particular composition may be selected for administration to a patient to supplement or complement a patient's microbiota in order to restore health or treat or prevent disease.
  • patients may be screened to determine the composition of their microbiota to determine the likelihood of successful treatment.
  • the bacterial compositions may be administered with other agents in a combination therapy mode, including anti-microbial agents and prebiotics.
  • Administration may be sequential, over a period of hours or days, or simultaneous.
  • the bacterial compositions are included in
  • combination therapy with one or more anti-microbial agents which include anti-bacterial agents, anti-fungal agents, anti-viral agents and anti-parasitic agents.
  • Anti-bacterial agents include cephalosporin antibiotics (cephalexin, cefuroxime, cefadroxil, cefazolin, cephalothin, cefaclor, cefamandole, cefoxitin, cefprozil, and ceftobiprole); fluoroquinolone antibiotics (cipro, Levaquin, floxin, tequin, avelox, and norflox); tetracycline antibiotics (tetracycline, minocycline, oxytetracycline, and
  • penicillin antibiotics amoxicillin, ampicillin, penicillin V, dicloxacillin, carbenicillin, vancomycin, and methicillin
  • carbapenem antibiotics ertapenem, doripenem, imipenem/cilastatin, and meropenem
  • Anti-viral agents include Abacavir, Acyclovir, Adefovir, Amprenavir, Atazanavir, Cidofovir, Darunavir, Delavirdine, Didanosine, Docosanol, Efavirenz, Elvitegravir, Emtricitabine, Enfuvirtide, Etravirine, Famciclovir, Foscarnet, Fomivirsen, Ganciclovir, Indinavir, Idoxuridine, Lamivudine, Lopinavir Maraviroc, MK-2048, Nelfinavir, Nevirapine, Penciclovir, Raltegravir, Rilpivirine, Ritonavir, Saquinavir, Stavudine, Tenofovir Trifluridine, Valaciclovir, Valganciclovir, Vidarabine, Ibacitabine, Amantadine, Oseltamivir, Rimantidine, Tipranavir, Zalcita
  • antifungal compounds include, but are not limited to polyene antifungals such as natamycin, rimocidin, filipin, nystatin, amphotericin B, candicin, and hamycin; imidazole antifungals such as miconazole, ketoconazole, clotrimazole, econazole, omoconazole, bifonazole, butoconazole, fenticonazole, isoconazole, oxiconazole, sertaconazole, sulconazole, and tioconazole; triazole antifungals such as fluconazole, itraconazole, isavuconazole, ravuconazole, posaconazole, voriconazole, terconazole, and albaconazole; thiazole antifungals such as abafungin; allylamine antifungals such as terbinafine, naftifine,
  • Other compounds that have antifungal properties include, but are not limited to polygodial, benzoic acid, ciclopirox, tolnaftate, undecylenic acid, flucytosine or 5-fluorocytosine, griseofulvin, and haloprogin.
  • the bacterial compositions are included in
  • combination therapy with one or more corticosteroids, mesalazine, mesalamine, sulfasalazine, sulfasalazine derivatives, immunosuppressive drugs, cyclosporin A, mercaptopurine, azathiopurine, prednisone, methotrexate, antihistamines,
  • glucocorticoids epinephrine, theophylline, cromolyn sodium, anti-leukotrienes, anticholinergic drugs for rhinitis, anti-cholinergic decongestants, mast-cell stabilizers, monoclonal anti-lgE antibodies, vaccines, and combinations thereof.
  • a prebiotic is a selectively fermented ingredient that allows specific changes, both in the composition and/or activity in the gastrointestinal microbiota that confers benefits upon host well-being and health.
  • Prebiotics may include complex carbohydrates, amino acids, peptides, or other essential nutritional components for the survival of the bacterial composition.
  • Prebiotics include, but are not limited to, amino acids, biotin, fructooligosaccharide, galactooligosaccharides, inulin, lactulose, mannan oligosaccharides, oligofructose-enriched inulin, oligofructose, oligodextrose, tagatose, trans-galactooligosaccharide, and xylooligosaccharides.
  • bacterial compositions are methods for testing certain characteristics of bacterial compositions. For example, the sensitivity of bacterial compositions to certain environmental variables is determined, e.g., in order to select for particular desirable characteristics in a given composition, formulation and/or use.
  • the constituents in the bacterial composition may be tested for pH resistance, bile acid resistance, and/or antibiotic sensitivity, either individually on a constituent-by- constituent basis or collectively as a bacterial composition comprised of multiple bacterial constituents (collectively referred to in this section as bacterial composition).
  • pH Sensitivity Testing If a bacterial composition will be administered other than to the colon or rectum (i.e., through, for example, but not limited to, an oral route), optionally testing for pH resistance enhances the selection of bacterial compositions that will survive at the highest yield possible through the varying pH environments of the distinct regions of the Gl tract. Understanding how the bacterial compositions react to the pH of the Gl tract also assists in formulation, so that the number of bacteria in a dosage form can be increased if beneficial and/or so that the composition may be administered in an enteric-coated capsule or tablet or with a buffering or protective composition.
  • bacterial compositions can be prepared that survive these varying pH ranges (specifically wherein at least 1 %, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or as much as 100% of the bacteria can survive gut transit times through various pH ranges). This may be tested by exposing the bacterial composition to varying pH ranges for the expected gut transit times through those pH ranges.
  • 18-hour cultures of bacterial compositions may be grown in standard media, such as gut microbiota medium ("GMM", see Goodman et al., Extensive personal human gut microbiota culture collections characterized and manipulated in gnotobiotic mice, PNAS 108(15):6252-6257 (201 1 )) or another animal-products-free medium, with the addition of pH adjusting agents for a pH of 1 to 2 for 30 minutes, a pH of 3 to 4 for 1 hour, a pH of 4 to 5 for 1 to 2 hours, and a pH of 6 to 7.4 for 2.5 to 3 hours.
  • GMM gut microbiota medium
  • PNAS 108(15):6252-6257 (201 1 ) or another animal-products-free medium
  • pH adjusting agents for a pH of 1 to 2 for 30 minutes, a pH of 3 to 4 for 1 hour, a pH of 4 to 5 for 1 to 2 hours, and a pH of 6 to 7.4 for 2.5 to 3 hours.
  • Bile Acid Sensitivity Testing enhances the selection of bacterial compositions that will survive exposures to bile acid during transit through the Gl tract.
  • Bile acids are secreted into the small intestine and can, like pH, affect the survival of bacterial compositions. This may be tested by exposing the bacterial compositions to bile acids for the expected gut exposure time to bile acids.
  • bile acid solutions may be prepared at desired concentrations using 0.05 mM Tris at pH 9 as the solvent. After the bile acid is dissolved, the pH of the solution may be adjusted to 7.2 with 10% HCI.
  • Bacterial compositions may be cultured in 2.2 ml of a bile acid composition mimicking the concentration and type of bile acids in the patient, 1 .0 ml of 10% sterile-filtered feces media and 0.1 ml of an 18-hour culture of the given strain of bacteria. Incubations may be conducted for from 2.5 to 3 hours or longer.
  • An alternative method for testing stability to bile acid is described in U.S. Patent No. 4,839,281 . Survival of bacteria may be determined by culturing the bacteria and counting colonies on appropriate selective or non-selective media.
  • bacterial compositions may be tested for sensitivity to antibiotics.
  • bacterial compositions may be chosen so that the bacterial constituents are sensitive to antibiotics such that if necessary they can be eliminated or substantially reduced from the patient's gastrointestinal tract by at least one antibiotic targeting the bacterial composition.
  • Adherence to Gastrointestinal Cells The bacterial compositions may optionally be tested for the ability to adhere to gastrointestinal cells. A method for testing adherence to gastrointestinal cells is described in U.S. Patent No. 4,839,281 .
  • Example 1 Construction of binary pairs in a high-throughput 96-well format. To allow high-throughput screening of binary pairs, vials of -80 °C glycerol stock banks were thawed and diluted to 1 e8 CFU/mL. Each strain was then diluted 10x (to a final concentration of 1 e7 CFU/mL of each strain) into 200 uL of PBS + 15% glycerol in the wells of a 96-well plate. Plates were then frozen at -80 °C. When needed, plates were removed from -80°C and thawed at room temperature under anaerobic conditions when testing in a CivSim with Clostridium difficile.
  • Example 2 Construction of ternary combinations in a high-throughput 96- well format. To allow high-throughput screening of ternary combinations, vials of -80 °C glycerol stock banks were thawed and diluted to 1 e8 CFU/mL. Each strain was then diluted 10x (to a final concentration of 1 e7 CFU/mL of each strain) into 200 uL of PBS + 15% glycerol in the wells of a 96-well plate. Plates were then frozen at -80 °C. When needed for the assay, plates were removed from -80 °C and thawed at room
  • Example 3 Construction of a CivSim Assay to Screen for EcobioticTM compositions Inhibitory to the Growth of Clostridium difficile.
  • An overnight culture of Clostridium difficile was grown under anaerobic conditions in SweetB-Fosln or other suitable media for the growth of C. difficile.
  • SweetB-Fosln is a complex media composed of brain heart infusion, yeast extract, cysteine, cellobiose, maltose, soluble starch, and fructooligosaccharides/inulin, and hemin, and is buffered with MOPs.
  • the culture was diluted 100,000 fold into a complex media such as SweetB-Fosln which is suitable for the growth of a wide variety of anaerobic bacterial species.
  • the diluted C. difficile mixture was then aliquoted to wells of a 96-well plate (180 uL to each well). 20 uL of a unique binary pair of potential inhibitory species was then added to each well at a final concentration of 1 e6 CFU/mL of each
  • the assay can be tested with binary pairs at different initial concentrations (1 e9 CFU/mL, 1 e8 CFU/mL, 1 e7 CFU/mL, 1 e5 CFU/mL, 1 e4 CFU/mL, 1 e3 CFU/mL, 1 e2 CFU/mL).
  • Control wells only inoculated with C. difficile were included for a comparison to the growth of C. difficile without inhibition. Additional wells were used for controls that either inhibit or do not inhibit the growth of C. difficile.
  • One example of a positive control that inhibits growth was a combination of Blautia producta, Clostridium bifermentans and Escherichia coli.
  • Example 4 Construction of a CivSim Assay to Screen for bacterial compositions that produce diffusible products inhibitory to the growth of Clostridium difficile using a filter insert .
  • the CivSim assay described above was modified by using a 0.22 uM filter insert (MilliporeTM MultiscreenTM 96-Well Assay Plates - Item
  • MAGVS2210) in 96-well format to physically separate C. difficile from the bacterial compositions.
  • the C. difficile was aliquoted into the 96-well plate while the bacterial compositions were aliquoted into media on the filter overlay.
  • the nutrient media as in contact on both sides of the 0.22 uM filter, allowing exchange of nutrients, small molecules and many macromolecules (e.g., bacteriocins, cell-surface proteins, or polysaccharides) by diffusion.
  • the filter insert containing the bacterial compositions was removed.
  • the plate containing C. difficile was then transferred to a 96-well plate reader suitable for measuring optical density (OD) at 600 nm. The growth of C. difficile in the presence of different bacterial compositions was compared based on the OD measurement.
  • CivSim Assay Construction of a CivSim Assay to Screen for bacterial compositions inhibitory to the growth of Clostridium difficile using Clostridium difficile selective media for quantification.
  • the CivSim assay described above can be modified to determine final C. difficile titer by serially diluting and plating to C. difficile selective media (Bloedt et al 2009) such as CCFA (cycloserine cefoxitin fructose agar, Anaerobe Systems), CDSA (Clostridium difficile selective agar, which is cycloserine cefoxitin mannitol agar, Becton Dickinson).
  • C. difficile selective media such as CCFA (cycloserine cefoxitin fructose agar, Anaerobe Systems), CDSA (Clostridium difficile selective agar, which is cycloserine cefoxitin mannitol agar, Becton Dickinson).
  • the standard curve was generated from a well on each assay plate containing only pathogenic C. difficile grown in SweetB + Fosln media as provided herein and quantified by selective spot plating. Serial dilutions of the culture were performed in sterile phosphate-buffered saline. Genomic DNA was extracted from the standard curve samples along with the other wells.
  • Genomic DNA was extracted from 5 ⁇ of each sample using a dilution, freeze/thaw, and heat lysis protocol. 5 ⁇ _ of thawed samples were added to 45 ⁇ _ of UltraPure water (Life Technologies, Carlsbad, CA) and mixed by pipetting. The plates with diluted samples were frozen at -20 °C until use for qPCR which includes a heated lysis step prior to amplification.
  • the genomic DNA could be isolated using the Mo Bio Powersoil ® -htp 96 Well Soil DNA Isolation Kit (Mo Bio Laboratories,
  • the qPCR reaction mixture contained 1 x SsoAdvanced Universal Probes Supermix, 900 nM of Wr-tcdB-F primer
  • thermocycling conditions were 95°C for 15 minutes followed by 45 cycles of 95°C for 5 seconds, 60°C for 30 seconds, and fluorescent readings of the FAM channel.
  • the qPCR could be performed with other standard methods known to those skilled in the art.
  • the Cq value for each well on the FAM channel was determined by the CFX ManagerTM 3.0 software.
  • the logio(cfu/mL) of C. difficile each experimental sample was calculated by inputting a given sample's Cq value into a linear regression model generated from the standard curve comparing the Cq values of the standard curve wells to the known logio(cfu/mL) of those samples.
  • the log inhibition was calculated for each sample by subtracting the logio(cfu/mL) of C. difficile in the sample from the
  • the pooled variance of all samples evaluated in the assay was estimated as the average of the sample variances weighted by the sample's degrees of freedom.
  • the pooled standard error was then calculated as the square root of the pooled variance divided by the square root of the number of samples.
  • Confidence intervals for the null hypothesis were determined by multiplying the pooled standard error to the z score corresponding to a given percentage threshold. Mean log inhibitions outside the confidence interval were considered to be inhibitory if positive or stimulatory if negative with the percent confidence corresponding to the interval used. Samples with mean log inhibition greater than the 99% confidence interval (C.I) of the null hypothesis are reported as ++++, those with a 95% ⁇ C.I.
  • Non-limiting but exemplary binary pairs include those with mean log reduction greater than 0.366, e.g. Allistipes shahii paired with Blautia producta, Clostridium hathaweyi, or Colinsella aerofaciens, or Clostidium mayombei paired with C. innocuum, C. tertium, Colinsella aerofaciens, or any of the other 424 combinations shown in Table 5.
  • CivSim assay describes binary pairs that do not effectively inhibit C. difficile.
  • 188 of 989 combinations promote growth with >80% confidence; 52 of 989 show a lack of inhibition with >90% confidence; 22 of 989 show a lack of inhibition with >95% confidence; 3 of 989, including B. producta combined with Coprococcus catus, Alistipes shahii combined with Dorea formicigenerans, and Eubacterium rectale combined with Roseburia intestinalis, show a lack of inhibition with >99% confidence.
  • 249 of 989 combinations are neutral in the assay, meaning they neither promote nor inhibit C. difficile growth to the limit of measurement.
  • CivSim shows that many ternary combinations inhibit C. difficile. 39 of 56 combinations show inhibition with a confidence interval >80%; 36 of 56 with a C.I. > 90%; 36 of 56 with a C.I. > 95%; 29 of 56 with a C.I. of >99%.
  • Non-limiting but exemplary ternary combinations include those with mean log reduction greater than 0.171 , e.g. any combination shown in Table 6 with a score of ++++, such as Colinsella aerofaciens, Coprococcus comes, and Blautia producta. Equally important, the CivSim assay describes ternary combinations that do not effectively inhibit C. difficile.
  • Genomic DNA is extracted from pure microbial cultures using a hot alkaline lysis method. 2 ⁇ of microbial culture is added to 18 ⁇ of Lysis Buffer (25mM NaOH, 0.2 mM EDTA) and the mixture is incubated at 95°C for 30 minutes.
  • Lysis Buffer 25mM NaOH, 0.2 mM EDTA
  • genomic DNA is extracted from pure microbial cultures using commercially available kits such as the Mo Bio Ultraclean® Microbial DNA Isolation Kit (Mo Bio Laboratories, Carlsbad, CA) or by standard methods known to those skilled in the art.
  • PCR reaction also contains 1 x HotMasterMix (5PRIME, Gaithersburg, MD), 250 nM of 27f primer (AGRGTTTGATCMTGGCTCAG, IDT, Coralville, IA), and 250 nM of 1492r primer (TACGGYTACCTTGTTAYGACTT, IDT, Coralville, IA), with Molecular Biology Grade Water (Mo Bio Laboratories, Carlsbad, CA) for the balance of the volume.
  • HotMasterMix 5PRIME, Gaithersburg, MD
  • 250 nM of 27f primer AGRGTTTGATCMTGGCTCAG, IDT, Coralville, IA
  • 1492r primer TACGGYTACCTTGTTAYGACTT, IDT, Coralville, IA
  • TACGGYTACCTTGTTAYGACTT Molecular Biology Grade Water
  • thermocyclers such as a BioRad MyCyclerTM Thermal Cycler (BioRad, Hercules, CA).
  • the reactions are run at 94°C for 2 minutes followed by 30 cycles of 94°C for 30 seconds, 51 °C for 30 seconds, and 68°C for 1 minute 30 seconds, followed by a 7 minute extension at 72°C and an indefinite hold at 4°C.
  • gel electrophoresis of a portion of the reaction products is used to confirm successful amplification of a ⁇ 1 .5 kb product.
  • Genomic DNA is extracted from pure microbial cultures using a hot alkaline lysis method. 2 ⁇ of microbial culture is added to 18 ⁇ of Lysis Buffer (25 mM NaOH, 0.2 mM EDTA) and the mixture is incubated at 95°C for 30 minutes.
  • Lysis Buffer 25 mM NaOH, 0.2 mM EDTA
  • genomic DNA is extracted from pure microbial cultures using commercially available kits such as the Mo Bio Ultraclean® Microbial DNA Isolation Kit (Mo Bio Laboratories, Carlsbad, CA) or by standard methods known to those in skilled in the art.
  • HotMasterMix (5PRIME, Gaithersburg, MD), 200 nM of V4_515f_adapt
  • adapters for lllumina sequencing by synthesis may incorporate adapters for lllumina sequencing by synthesis.
  • identical replicate, triplicate, or quadruplicate reactions may be performed.
  • other universal bacterial primers or thermostable polymerases known to those skilled in the art are used.
  • thermocyclers such as a BioRad MyCyclerTM Thermal Cycler (BioRad, Hercules, CA).
  • the reactions are run at 94°C for 3 minutes followed by 25 cycles of 94°C for 45 seconds, 50°C for 1 minute, and 72°C for 1 minute 30 seconds, followed by a 10 minute extension at 72°C and a indefinite hold at 4°C.
  • gel electrophoresis of a portion of the reaction products is used to confirm successful amplification of a -0.4 kb product.
  • the prepared library is sequenced on lllumina HiSeq or MiSeq sequencers (lllumina, San Diego, CA) with cluster generation, template hybridization, iso-thermal amplification, linearization, blocking and denaturization and hybridization of the sequencing primers performed according to the manufacturer's instructions.
  • 16SV4SeqFw (TATGGTAATTGTGTGCCAGCMGCCGCGGTAA), 16SV4SeqRev (AGTCAGTCAGCCGGACTACHVGGGTWTCTAAT), and 16SV4lndex
  • OTUs in the dataset are defined.
  • the certainty of the OTU call is defined based on the OTU's sequence similarity to a reference nucleic acid sequence and the proximity of the OTU sequence relative to one or more reference sequences in the phylogeny.
  • the specificity of an OTU's taxonomic and phlylogenetic assignment determines whether the match is assigned at the level of Family, Genus, Species, or Strain, and the confidence of this assignment is determined based on the position of bootstrap supported branches in the reference phylogenetic tree relative to the placement of the OTU sequence being interrogated.
  • Example P3 Construction of an In Vitro Assay to Screen for Combinations of Microbes Inhibitory to the Growth of Pathogenic E. coli
  • the in vitro assay is used to screen for combinations of bacteria inhibitory to the growth of E. coli by modifying the media used for growth of the pathogen inoculum.
  • One of several choices of media is used for growth of the pathogen such as Reinforced Clostridial Media (RCM), Brain Heart Infusion Broth (BHI) or Luria Bertani Broth (LB) (also known as Lysogeny Broth).
  • E. coli is quantified by using alternative selective media specific for E. coli or using qPCR probes specific for the pathogen. For example, aerobic growth on MacConkey lactose medium selects for enteric Gram negatives, including E. coli. qPCR is conducted using probes specific for the shiga toxin of pathogenic E. coli.
  • EXAMPLE P Construction of an In Vitro Assay to Screen for Combinations of Microbes Inhibitory to the Growth of Vancomycin-Resistant Enterococcus (VRE)
  • the in vitro assay is used to screen for combinations of bacteria inhibitory to the growth of Vancomycin-Resistant Enterococcus spp. (VRE) by modifying the media used for growth of the pathogen inoculum.
  • VRE Vancomycin-Resistant Enterococcus spp.
  • Several choices of media are used for growth of the pathogen such as Reinforced Clostridial Media (RCM), Brain Heart Infusion Broth (BHI) or Luria Bertani Broth (LB).
  • RCM Reinforced Clostridial Media
  • BHI Brain Heart Infusion Broth
  • LB Luria Bertani Broth
  • VRE is quantified by using alternative selective media specific for VRE or using qPCR probes specific for the pathogen.
  • m-Enterococcus agar containing sodium azide is selective for Enterococcus spp. and a small number of other species. Probes specific to the van genes conferring vancomycin resistance are used in the qPCR.
  • the in vitro assay is used to screen for combinations of bacteria inhibitory to the growth of Salmonella spp. by modifying the media used for growth of the pathogen inoculum.
  • media such as Reinforced Clostridial Media (RCM), Brain Heart Infusion Broth (BHI) or Luria Bertani Broth (LB).
  • Salmonella spp. are quantified by using alternative selective media specific for Salmonella spp. or using qPCR probes specific for the pathogen.
  • MacConkey agar is used to select for Salmonella spp. and the invA gene is targeted with qPCR probes; this gene encodes an invasion protein carried by many pathogenic Salmonella spp. and is used in invading eukaryotic cells.
  • EXAMPLE P6 Method of Preparing the Bacterial Composition for Administration to a Subject
  • strains for the bacterial composition are independently cultured and mixed together before administration. Both strains are independently be grown at 37°C, pH 7, in a GMM or other animal-products-free medium, pre-reduced with 1 g/L cysteine e HCI. After each strain reaches a sufficient biomass, it is preserved for banking by adding 15% glycerol and then frozen at -80°C in 1 ml cryotubes.
  • Each strain is then be cultivated to a concentration of 10 10 CFU/mL, then concentrated 20-fold by tangential flow microfiltration; the spent medium is exchanged by diafiltering with a preservative medium consisting of 2% gelatin, 100 mM trehalose, and 10 mM sodium phosphate buffer, or other suitable preservative medium.
  • the suspension is freeze-dried to a powder and titrated.
  • the powder is blended with microcrystalline cellulose and magnesium stearate and formulated into a 250 mg gelatin capsule containing 10 mg of lyophilized powder (10 8 to 10 1 1 bacteria), 160 mg microcrystalline cellulose, 77.5 mg gelatin, and 2.5 mg magnesium stearate.
  • EXAMPLE P7 Method of Treating a Subject with a Bacterial Composition
  • a patient has suffered from recurrent bouts of C. difficile.
  • the patient is treated with an antibiotic sufficient to ameliorate the symptoms of the illness.
  • the patient is administered one of the present bacterial compositions.
  • Bacillus circulans and Roseburia inulinivorans at a dose of 10 8 bacteria total in a lyophilized form, specifically in a 250 mg gelatin capsule containing 10 mg of lyophilized bacteria, 160 mg microcrystalline cellulose, 77.5 mg gelatin, and 2.5 mg magnesium stearate.
  • the patient takes the capsule by mouth and resumes a normal diet after 4, 8, 12, or 24 hours.
  • the patient may take the capsule by mouth before, during, or immediately after a meal.
  • Feces is collected before and at 1 day, 3 days, 1 week, and 1 month after administration.
  • the presence of C. difficile is found in the feces before administration of the bacterial composition, but feces collections after administration show reducing (such as at least 50% less, 60%, 70%, 80%, 90%, or 95%) to no detectable levels of C.
  • ELISA for toxin protein or traditional microbiological identification techniques may also be used.
  • a positive response may be defined as absence of diarrhea, which itself is defined as 3 or more loose or watery stools per day for at least 2 consecutive days or 8 or more loose or watery stools in 48 hours, or persisting diarrhea (due to other causes) with repeating (three times) negative stool tests for toxins of C. difficile.
  • Treatment failure is defined as persisting diarrhea with a positive C.
  • C. difficile toxin stool test or no reduction in levels of C. difficile, as measured by qPCR sequencing.
  • ELISA or traditional microbiological identification techniques may also be used.
  • EXAMPLE P8 Method of Treating a Subject with a Bacterial Composition
  • a patient has suffered from recurrent bouts of C. difficile.
  • the patient is treated with an antibiotic sufficient to ameliorate the symptoms of the illness.
  • the patient is administered one of the present bacterial compositions.
  • the patient is administered a bacterial composition containing two bacterial types from Table 1 or Table 3, or a combination from Table 2, at a dose of 10 8 bacteria total in a lyophilized form formulated in an enteric coated capsule.
  • Example of the patient or samples derived from the patient is expected to demonstrate at least one measure of success as described herein (reducing levels of C. difficile as measured by qPCR, ELISA, or traditional microbiological identification; absence of diarrhea; persisting diarrhea with repeating (three times) negative stool tests for toxins of C. difficile.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PCT/US2013/071758 2012-11-23 2013-11-25 Synergistic bacterial compositions and methods of production and use thereof Ceased WO2014082050A1 (en)

Priority Applications (31)

Application Number Priority Date Filing Date Title
NZ709392A NZ709392A (en) 2012-11-23 2013-11-25 Synergistic bacterial compositions and methods of production and use thereof
BR112015011933A BR112015011933A8 (pt) 2012-11-23 2013-11-25 Composições bacterianas sinérgicas e métodos de produção e uso das mesmas
KR1020157016626A KR102426653B1 (ko) 2012-11-23 2013-11-25 상승작용적 박테리아 조성물, 그리고 이의 제조 방법 및 용도
SG11201503966PA SG11201503966PA (en) 2012-11-23 2013-11-25 Synergistic bacterial compositions and methods of production and use thereof
RU2015124366A RU2724666C2 (ru) 2012-11-23 2013-11-25 Синергетические бактериальные композиции и способы их получения и применения
AU2013347805A AU2013347805C1 (en) 2012-11-23 2013-11-25 Synergistic bacterial compositions and methods of production and use thereof
JP2015544179A JP6506173B2 (ja) 2012-11-23 2013-11-25 相乗的細菌組成物並びにその生成及び使用の方法
KR1020227025731A KR102617655B1 (ko) 2012-11-23 2013-11-25 상승작용적 박테리아 조성물, 그리고 이의 제조 방법 및 용도
CN201380071190.XA CN104955466A (zh) 2012-11-23 2013-11-25 协同细菌组合物和其制造方法和用途
MX2015006491A MX2015006491A (es) 2012-11-23 2013-11-25 Composiciones bacterianas sinergicas y metodos de produccion y uso de las mismas.
CA2892297A CA2892297C (en) 2012-11-23 2013-11-25 Synergistic bacterial compositions and methods of production and use thereof
HK16106857.1A HK1218836A1 (zh) 2012-11-23 2013-11-25 协同细菌组合物和其制造方法和用途
EP19194787.8A EP3628161B1 (en) 2012-11-23 2013-11-25 Synergistic bacterial compositions and methods of production and use thereof
EP13856249.1A EP2953472A4 (en) 2012-11-23 2013-11-25 Synergistic bacterial compositions and methods of production and use thereof
EP23160605.4A EP4233545A3 (en) 2012-11-23 2013-11-25 Synergistic bacterial compositions and methods of production and use thereof
US14/091,201 US8906668B2 (en) 2012-11-23 2013-11-26 Synergistic bacterial compositions and methods of production and use thereof
US14/221,190 US9028841B2 (en) 2012-11-23 2014-03-20 Synergistic bacterial compositions and methods of production and use thereof
US14/592,481 US9533014B2 (en) 2012-11-23 2015-01-08 Synergistic bacterial compositions and methods of production and use thereof
IL238973A IL238973A0 (en) 2012-11-23 2015-05-21 Synergistic bacterial preparations, methods for their preparation and use
US15/359,439 US20170165302A1 (en) 2012-11-23 2016-11-22 Synergistic bacterial compositions and methods of production and use thereof
AU2018204406A AU2018204406B2 (en) 2012-11-23 2018-06-19 Synergistic bacterial compositions and methods of production and use thereof
US16/223,008 US10864235B2 (en) 2012-11-23 2018-12-17 Synergistic bacterial compositions and methods of production and use thereof
AU2020201598A AU2020201598C1 (en) 2012-11-23 2020-03-03 Synergistic bacterial compositions and methods of production and use thereof
US17/120,657 US11458173B2 (en) 2012-11-23 2020-12-14 Synergistic bacterial compositions and methods of production and use thereof
US17/120,666 US11458174B2 (en) 2012-11-23 2020-12-14 Synergistic bacterial compositions and methods of production and use thereof
US17/120,647 US11389490B2 (en) 2012-11-23 2020-12-14 Synergistic bacterial compositions and methods of production and use thereof
US17/120,671 US11464812B2 (en) 2012-11-23 2020-12-14 Synergistic bacterial compositions and methods of production and use thereof
AU2022204478A AU2022204478A1 (en) 2012-11-23 2022-06-24 Synergistic bacterial compositions and methods of production and use thereof
US17/938,184 US12083151B2 (en) 2012-11-23 2022-10-05 Synergistic bacterial compositions and methods of production and use thereof
AU2024204663A AU2024204663A1 (en) 2012-11-23 2024-07-05 Synergistic bacterial compositions and methods of production and use thereof
US18/792,910 US20250064869A1 (en) 2012-11-23 2024-08-02 Synergistic bacterial compositions and methods of production and use thereof

Applications Claiming Priority (22)

Application Number Priority Date Filing Date Title
US201261729527P 2012-11-23 2012-11-23
US201261729524P 2012-11-23 2012-11-23
US201261729515P 2012-11-23 2012-11-23
US201261729517P 2012-11-23 2012-11-23
US201261729519P 2012-11-23 2012-11-23
US201261729525P 2012-11-23 2012-11-23
US201261729526P 2012-11-23 2012-11-23
US201261729520P 2012-11-23 2012-11-23
US201261729518P 2012-11-23 2012-11-23
US201261729521P 2012-11-23 2012-11-23
US201261729522P 2012-11-23 2012-11-23
US61/729,517 2012-11-23
US61/729,520 2012-11-23
US61/729,519 2012-11-23
US61/729,515 2012-11-23
US61/729,527 2012-11-23
US61/729,518 2012-11-23
US61/729,526 2012-11-23
US61/729,524 2012-11-23
US61/729,522 2012-11-23
US61/729,521 2012-11-23
US61/729,525 2012-11-23

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/091,201 Continuation US8906668B2 (en) 2012-11-23 2013-11-26 Synergistic bacterial compositions and methods of production and use thereof
US14/091,201 Continuation-In-Part US8906668B2 (en) 2012-11-23 2013-11-26 Synergistic bacterial compositions and methods of production and use thereof

Publications (1)

Publication Number Publication Date
WO2014082050A1 true WO2014082050A1 (en) 2014-05-30

Family

ID=50776593

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/071758 Ceased WO2014082050A1 (en) 2012-11-23 2013-11-25 Synergistic bacterial compositions and methods of production and use thereof

Country Status (20)

Country Link
US (2) US12083151B2 (enExample)
EP (3) EP2953472A4 (enExample)
JP (4) JP6506173B2 (enExample)
KR (2) KR102617655B1 (enExample)
CN (1) CN104955466A (enExample)
AU (5) AU2013347805C1 (enExample)
BR (1) BR112015011933A8 (enExample)
CA (3) CA3212215A1 (enExample)
DK (1) DK3628161T3 (enExample)
ES (1) ES2949659T3 (enExample)
FI (1) FI3628161T3 (enExample)
HK (1) HK1218836A1 (enExample)
IL (1) IL238973A0 (enExample)
MX (1) MX2015006491A (enExample)
NZ (1) NZ709392A (enExample)
PL (1) PL3628161T3 (enExample)
PT (1) PT3628161T (enExample)
RU (1) RU2724666C2 (enExample)
SG (2) SG11201503966PA (enExample)
WO (1) WO2014082050A1 (enExample)

Cited By (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105012350A (zh) * 2015-08-06 2015-11-04 温州医科大学 益生菌丁酸梭菌菌株
US9433651B2 (en) 2013-06-05 2016-09-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9446080B2 (en) 2013-02-04 2016-09-20 Seres Therapeutics, Inc. Compositions and methods
US9486487B2 (en) 2014-10-31 2016-11-08 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9533014B2 (en) 2012-11-23 2017-01-03 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
WO2017008026A1 (en) * 2015-07-08 2017-01-12 Seres Therapeutics, Inc. Methods of treating colitis
WO2017091753A1 (en) * 2015-11-25 2017-06-01 Memorial Sloan-Kettering Cancer Center Methods and compositions for reducing vancomycin-resistant enterococci infection or colonization
WO2017091694A1 (en) * 2015-11-24 2017-06-01 Memorial Sloan-Kettering Cancer Center Methods and compositions for identifying and treating subjects at risk for checkpoint blockade therapy associated colitis
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
WO2017091783A3 (en) * 2015-11-24 2017-07-13 Seres Therapeutics, Inc. Designed bacterial compositions
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US20170354695A1 (en) * 2015-06-15 2017-12-14 4D Pharma Research Limited Compositions comprising bacterial strains
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
KR20180048696A (ko) * 2015-08-11 2018-05-10 유니베르시타트 데 지로나 패칼리박테리움 프라우스니치이 파일로군 i /또는 파일로군 ii 구성원을 정량하는 방법 및 바이오마커로서의 그 용도
US9999641B2 (en) 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
US10076546B2 (en) 2013-03-15 2018-09-18 Seres Therapeutics, Inc. Network-based microbial compositions and methods
WO2018172483A1 (en) * 2017-03-22 2018-09-27 Assistance Publique - Hopitaux De Paris Method for determining the potential efficacy of anticancer treatment
US10149870B2 (en) 2012-02-29 2018-12-11 The General Hospital Corporation Compositions of microbiota and methods related thereto
CN109072173A (zh) * 2016-09-06 2018-12-21 深圳华大生命科学研究院 克里斯坦森氏菌(Christensenella intestinihominis)及其应用
US10226431B2 (en) 2015-06-09 2019-03-12 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10258655B2 (en) 2013-11-25 2019-04-16 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US10322151B2 (en) 2015-06-15 2019-06-18 4D Pharma Research Limited Compositions comprising bacterial strains
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10391128B2 (en) 2015-11-23 2019-08-27 4D Pharma Research Limited Compositions comprising bacterial strains
US10391130B2 (en) 2015-06-15 2019-08-27 4D Pharma Research Limited Compositions comprising bacterial strains
US10456444B2 (en) 2014-12-23 2019-10-29 4D Pharma Research Limited Pirin polypeptide and immune modulation
US10471108B2 (en) 2015-11-20 2019-11-12 4D Pharma Research Limited Compositions comprising bacterial strains
US10485830B2 (en) 2016-12-12 2019-11-26 4D Pharma Plc Compositions comprising bacterial strains
US10500237B2 (en) 2015-06-15 2019-12-10 4D Pharma Research Limited Compositions comprising bacterial strains
US10583158B2 (en) 2016-03-04 2020-03-10 4D Pharma Plc Compositions comprising bacterial strains
US10610550B2 (en) 2015-11-20 2020-04-07 4D Pharma Research Limited Compositions comprising bacterial strains
US10610548B2 (en) 2016-07-13 2020-04-07 4D Pharma Plc Compositions comprising bacterial strains
US10633714B2 (en) 2013-07-21 2020-04-28 Pendulum Therapeutics, Inc. Methods and systems for microbiome characterization, monitoring and treatment
US10736926B2 (en) 2015-06-15 2020-08-11 4D Pharma Research Limited Compositions comprising bacterial strains
US10744166B2 (en) 2015-11-23 2020-08-18 4D Pharma Research Limited Compositions comprising bacterial strains
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
IT201900006056A1 (it) * 2019-04-18 2020-10-18 Probiotical Spa Procedimento per la preparazione di una biomassa di cellule di batteri liofilizzate stabili e determinazione della loro stabilità mediante un metodo citofluorimetrico
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
CN111991404A (zh) * 2020-10-10 2020-11-27 西南医科大学 防治真菌感染的复合维生素d及其应用
US10851137B2 (en) 2013-04-10 2020-12-01 4D Pharma Research Limited Polypeptide and immune modulation
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10973861B2 (en) 2013-02-04 2021-04-13 Seres Therapeutics, Inc. Compositions and methods
US10987387B2 (en) 2017-05-24 2021-04-27 4D Pharma Research Limited Compositions comprising bacterial strain
US11007233B2 (en) 2017-06-14 2021-05-18 4D Pharma Research Limited Compositions comprising a bacterial strain of the genus Megasphera and uses thereof
US11013773B2 (en) 2011-07-14 2021-05-25 4D Pharma Research Limited Lactic acid bacterial strains
WO2021163212A1 (en) * 2020-02-10 2021-08-19 Native Microbials, Inc. Microbial compositions and methods of use for canine enteropathy and dysbiosis
WO2021183701A1 (en) * 2020-03-10 2021-09-16 Federation Bio Inc. Microbial consortia for the treatment of disease
US11123379B2 (en) 2017-06-14 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US11123378B2 (en) 2017-05-22 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US11224620B2 (en) 2016-07-13 2022-01-18 4D Pharma Plc Compositions comprising bacterial strains
US11266698B2 (en) 2011-10-07 2022-03-08 4D Pharma Research Limited Bacterium for use as a probiotic for nutritional and medical applications
RU2773327C2 (ru) * 2015-11-24 2022-06-02 Серес Терапеутикс, Инк. Разработанные бактериальные композиции
US11369644B2 (en) 2018-04-10 2022-06-28 Siolta Therapeutics, Inc. Microbial consortia
US11406675B2 (en) 2019-10-07 2022-08-09 Siolta Therapeutics, Inc. Therapeutic pharmaceutical compositions
US11419902B2 (en) 2018-05-11 2022-08-23 4D Pharma Research Limited Compositions comprising bacterial strains
WO2023283681A1 (en) * 2021-07-10 2023-01-19 Microba Ip Pty Ltd Compositions and methods for treating disease ii
US11583558B2 (en) 2017-08-30 2023-02-21 Pendulum Therapeutics, Inc. Methods and compositions for treatment of microbiome-associated disorders
US11701394B2 (en) 2017-08-14 2023-07-18 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
US11723933B2 (en) 2014-12-23 2023-08-15 Cj Bioscience, Inc. Composition of bacteroides thetaiotaomicron for immune modulation
WO2023199057A1 (en) 2022-04-13 2023-10-19 Brunel University London Compositions for preventing and treating infection comprising an artificial sweetener
US11986500B2 (en) 2010-02-01 2024-05-21 Rebiotix Inc Bacteriotherapy for clostridium difficile colitis
US12048720B2 (en) 2017-06-14 2024-07-30 Cj Bioscience, Inc. Compositions comprising bacterial strains
US12083151B2 (en) 2012-11-23 2024-09-10 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US12161680B2 (en) 2018-08-17 2024-12-10 Vedanta Biosciences, Inc. Methods of decreasing dysbiosis and restoring a microbiome
US12214002B2 (en) 2017-10-30 2025-02-04 Seres Therapeutics, Inc. Compositions and methods for treating antibiotic resistance
US12343360B2 (en) 2018-07-19 2025-07-01 Pendulum Therapeutics Inc Methods and compositions for microbial engraftment
EP4250932A4 (en) * 2020-11-25 2025-07-30 Seres Therapeutics Inc BACTERIAL COMPOSITIONS DESIGNED TO TREAT GRAFT-VERSE-HOST DISEASE
US12390498B2 (en) 2016-06-14 2025-08-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
US12478649B2 (en) * 2019-01-31 2025-11-25 The Chinese University Of Hong Kong Therapeutic and prophylactic treatment for colorectal cancer

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2018130698A (ru) * 2016-01-25 2020-02-27 Новозимс А/С Способ уменьшения микробного налета в инкубаторе для сельскохозяйственной птицы
ES2960781T3 (es) 2016-02-04 2024-03-06 Univ Gent Uso de comunidades microbianas para la salud humana y animal
CN115919906A (zh) * 2016-03-04 2023-04-07 加利福尼亚大学董事会 微生物聚生体及其用途
ES2987655T7 (en) * 2016-04-19 2025-04-29 Genome Res Ltd Bacteriotherapy
CN107460140B (zh) * 2016-06-02 2020-11-13 浙江科技学院 一种芽孢杆菌hz16中抑制军团菌活性物的制备方法
WO2018027898A1 (zh) * 2016-08-12 2018-02-15 深圳华大基因研究院 一种产丁酸栖粪杆菌及其培养方法和应用
CN109219656B (zh) * 2016-09-06 2025-12-09 深圳华大生命科学研究院 长栖粪杆菌（Faecalibacterium longum）及其应用
KR101978068B1 (ko) * 2016-11-25 2019-08-28 서울대학교산학협력단 신규한 페디오코커스 악시딜락티시를 이용한 돼지 설사증 예방 또는 치료용 조성물
CN111432825A (zh) * 2017-10-03 2020-07-17 赛里斯治疗公司 色胺代谢的操纵
MA53617A (fr) * 2018-09-10 2021-07-21 Riken Composition pour inhiber l'activité de la trypsine, contenant, en tant que principe actif, une bactérie appartenant au genre paraprevotella
KR102269450B1 (ko) * 2018-09-14 2021-06-25 연세대학교 산학협력단 장내 병원성 세균에 대한 항균 활성 균주 및 이를 포함하는 병원성 장내 세균 유발성 질환의 예방 또는 치료용 약학적 조성물
KR102064134B1 (ko) * 2019-09-10 2020-01-08 재단법인 농축산용미생물산업육성지원센터 신균주 페디오코쿠스 에시딜락티시 cacc 537 및 이를 유효성분으로 함유하는 반려동물용 사료 조성물
CA3165418A1 (en) * 2019-12-27 2021-07-01 Evelo Biosciences, Inc. Solid dosage forms containing bacteria and microbial extracellular vesicles
IL271778A (en) * 2019-12-31 2021-06-30 Ichilov Tech Ltd Methods for treating atopic dermatitis
WO2021195577A2 (en) * 2020-03-26 2021-09-30 Persephone Biosciences, Inc. Compositions for modulating gut microflora populations, enhancing drug potency and treating viral infections, and methods for making and using same
CN113549671B (zh) * 2021-07-21 2023-09-08 连云港市第一人民医院 一种诊断维持性血液透析患者肌少症的肠道菌群
CN114438133B (zh) * 2022-02-15 2023-10-27 合肥工业大学 菊粉发酵物、其制备方法及在防治动物结肠癌中的用途
KR102620190B1 (ko) * 2022-08-31 2024-01-04 주식회사 바이오뱅크힐링 아가토박터 렉탈리스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
CN115305226B (zh) * 2022-09-22 2023-06-16 郑州轻工业大学 一株降解烟碱并产氢的抗辐射不动杆菌zj-22及其应用
KR20240114298A (ko) * 2023-01-12 2024-07-23 에스엔제이 파마 인크 감염 저항성 장내 균주 및 그 용도
KR102753068B1 (ko) * 2023-03-08 2025-01-16 주식회사 빙그레 신규한 락토바실러스 플란타룸 fb091 균주 및 이를 포함하는 식품 조성물
WO2024249585A1 (en) * 2023-05-31 2024-12-05 The Regents Of The University Of California Compositions and methods for treating mental and metabolic disorders
KR102803865B1 (ko) * 2023-07-31 2025-05-09 전라남도 사료첨가제 및 이를 포함하는 사료 조성물
CN117363763B (zh) * 2023-11-02 2025-05-27 美益添生物医药(武汉)有限公司 一种与功能性便秘相关的微生物标志物组合及其应用
CN118147023B (zh) * 2024-05-13 2024-07-19 山东润德生物科技有限公司 一种复合发酵剂及在制备n-乙酰神经氨酸中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070141139A1 (en) * 2000-01-27 2007-06-21 Peros Systems Technologies Inc. Composition for intestinal delivery
US20110189132A1 (en) * 2010-02-01 2011-08-04 Microbios, Inc. Microbial product containing multiple microorganisms
US8187590B2 (en) * 1998-08-24 2012-05-29 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US20120276201A1 (en) * 2009-12-31 2012-11-01 Ira Milton Trachtman Compositions and method for treatment and prophylaxis of inflammatory bowel disease

Family Cites Families (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3009864A (en) 1958-09-18 1961-11-21 Union Carbide Corp Process control
US3228838A (en) 1959-04-23 1966-01-11 Union Carbide Corp Preservation of biological substances
US3009861A (en) 1961-01-13 1961-11-21 Alderton Gordon Isolation of bacterial spores
US3608030A (en) 1969-05-21 1971-09-21 Howard Tint Method of preparing a tablet dosage-form for the immunization of the intestinal tract with live virus preparations
US4077227A (en) 1976-11-12 1978-03-07 Regents Of The University Of Minnesota Method of freezing liquid material in which agglomeration is inhibited
US4205132A (en) 1978-07-17 1980-05-27 Microlife Technics, Inc. Lyophilization of bacteria
FI59925C (fi) 1980-01-11 1981-11-10 Esko Viljo Nurmi Foerfarande foer framstaellning av ett bakteriepreparat anvaendbart foer foerhindrande av salmonellainfektion hos fjaederfae
US4655047A (en) 1985-03-25 1987-04-07 I.Q.F. Inc. Process for freezing or chilling
US4839281A (en) 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
EP0439453B1 (en) 1987-10-12 1994-01-19 Exomed Australia Pty. Ltd. (ACN 051 976 446) Improved method for treatment of gastrointestinal disorders
US5045446A (en) 1988-08-26 1991-09-03 Cryopharm Corporation Lyophilization of cells
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
WO1990001335A1 (en) 1988-08-02 1990-02-22 Borody Thomas J Treatment of gastro-intestinal disorders
GB2233343B (en) 1989-06-30 1993-07-07 Farmos Oy A bacterial preparation for use in poultry
JP2961182B2 (ja) * 1990-03-09 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
JP2961184B2 (ja) * 1990-05-07 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
US5436002A (en) 1991-01-29 1995-07-25 Mycogen Corporation Bacillus thuringiensisisolate PS201T6 toxin
RU2035186C1 (ru) * 1992-07-09 1995-05-20 Семен Рафаилович Резник Профилактический биопрепарат споролакт
CA2146747C (en) 1992-10-09 2006-12-19 Brian A. Naughton Liver reserve cells
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
WO1997008598A1 (de) 1995-08-25 1997-03-06 Gff Technopark Verfahren zur simultanen, digitalen phasenempfindlichen detektion von zeitaufgelösten, quasi-gleichzeitig erfassten datenarrays eines periodisch stimulierten systems
DE69635496T2 (de) 1995-09-15 2006-07-27 Gerding, Dale N., Chicago Verfahren und zusammensetzung zur vorbeugung und behandlung von mit clostridium difficile assoziierten erkrankungen
AUPO430496A0 (en) 1996-12-19 1997-01-23 Arnott's Biscuits Limited Prebiotics and probiotics
US5965128A (en) 1997-08-13 1999-10-12 University Of Georgia Research Foundation Inc. Control of enterohemorrhagic E. coli 0157:H7 in cattle by probiotic bacteria and specific strains of E. coli
US5951977A (en) 1997-10-14 1999-09-14 The United States Of America, As Represented By The Secretary Of Agriculture Competitive exclusion culture for swine
US6589771B1 (en) 1999-10-28 2003-07-08 Immunom Technologies, Inc. Methods for arousing dormant bacteria
US6613549B2 (en) 2000-02-10 2003-09-02 Urex Biotech, Inc. Probiotic therapy for newborns
AU2002221004B2 (en) * 2000-11-30 2007-01-25 The Bio Balance Corp. Preparation of compositions comprising bacterial strains and volatile plant extracts and therapeutic and industrial applications thereof
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
MXPA03009877A (es) 2001-05-04 2005-07-15 Univ Florida Clonacion y secuenciamiento de genes de piruvato decarboxilasa (pdc) a partir de bacterias y usos de los mismos.
ITMI20011632A1 (it) 2001-07-27 2003-01-27 Sanofi Synthelabo Composizione solida contenente spore di batteri non patogeni del genere bacillus
GB0130789D0 (en) 2001-12-21 2002-02-06 King S College London Application of spores
US8383342B2 (en) 2002-04-24 2013-02-26 The University Of North Carolina At Greensboro Compositions, products, methods and systems to monitor water and other ecosystems
GB0212975D0 (en) 2002-06-06 2002-07-17 Mars Uk Ltd Mammalian animal composition
AU2002951692A0 (en) 2002-09-23 2002-10-17 Vital Biotech (Hong Kong) Limited Improvements in or relating to vaccines
US20050180962A1 (en) 2003-01-30 2005-08-18 Eyal Raz Inactivated probiotic bacteria and methods of use thereof
CA2559596A1 (en) 2003-03-13 2004-11-25 Universite De Moncton (Bureau De Soutien A L'innovation) Antioxidant producing bacterium and uses thereof
EP1631312B1 (en) 2003-04-23 2008-09-10 Medarex, Inc. Compositions and methods for the therapy of inflammatory bowel disease
US20060046246A1 (en) 2003-04-24 2006-03-02 Qiandong Zeng Genus, group, species and/or strain specific 16S rDNA sequences
WO2004104175A2 (en) 2003-05-14 2004-12-02 University Of Georgia Research Foundation, Inc. Probiotic bacteria and methods
MXPA06001821A (es) * 2003-08-18 2006-05-31 Bio Balance Corp Una composicion probiotica, liquida, estable, preparacion y aplicaciones de la misma.
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
US20050048515A1 (en) 2003-08-29 2005-03-03 Garner Bryan E. Methods for detecting and quantifying specific probiotic microorganisms in animal feed
US20050239706A1 (en) 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
WO2005074706A1 (en) 2004-02-03 2005-08-18 Universite De Montreal Use of live bacteria for growth promotion in animals
US7632520B2 (en) 2004-02-16 2009-12-15 Sanjeev Khandelwal Synergistic antibacterial formulation and to a method of making the same
US7854927B2 (en) 2004-05-11 2010-12-21 Ganeden Biotech, Inc. Methods and compositions for the dietary management of autoimmune disorders
EP2280085A3 (en) 2004-11-01 2011-02-23 George Mason University Compositions and methods for diagnosing colon disorders
CA2586299C (en) 2004-11-01 2014-10-28 James W. Stave Method for detecting or enriching a target microorganism upon lysis of non-target bacteria with bacteriophage
US20060188523A1 (en) 2005-01-10 2006-08-24 Zhiheng Pei Methods for diagnosing and treating chronic tonsillitis
US7993667B2 (en) 2005-03-25 2011-08-09 Kimberly-Clark Worldwide, Inc. Methods of manufacturing a medicated tampon assembly
BRPI0611492B1 (pt) 2005-05-31 2021-10-13 Mars, Incorporated Bifidobactéria probiótica felina
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
JP5363811B2 (ja) 2005-09-28 2013-12-11 ノルディスク リバランス アクティーゼルスカブ 治療エフェクターとしてプロバイオティック細菌と発酵穀物を用いるｉｂｄ及びｉｂｓの治療
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
WO2007136553A2 (en) * 2006-05-18 2007-11-29 Biobalance Llc Bacterial strains, compositions including same and probiotic use thereof
JP5019563B2 (ja) 2006-06-16 2012-09-05 旭化成ケミカルズ株式会社 腸内細菌賦活剤
CN101472639A (zh) 2006-06-20 2009-07-01 皇家飞利浦电子股份有限公司 用于治疗胃肠疾病的电子胶囊
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
EE05459B1 (et) * 2006-12-08 2011-08-15 Tartu �likool Sporogeense Bacillus smithii tvi TBMI12 MSCL P737 ja selle endospooride kasutamine probiootikumina, toidulisandina ning probiootiline kompositsioon
WO2008076696A2 (en) 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
DE102006062250A1 (de) 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
WO2008083157A2 (en) 2006-12-29 2008-07-10 Washington University In St. Louis Altering pgc-1alapha, ampk, fiaf, or the gastrointestinal microbiota as a means to modulate body fat and/or weight loss in a subject
CA2699550C (en) 2007-09-12 2020-08-18 Targanta Therapeutics Corp. Method of inhibiting clostridium difficile by administration of oritavancin
US8236508B2 (en) 2008-01-29 2012-08-07 Drexel University Detecting and measuring live pathogens utilizing a mass detection device
US8021654B2 (en) 2008-03-14 2011-09-20 Danisco A/S Methods of treating pigs with Bacillus strains
CA2720292A1 (en) 2008-04-01 2009-10-08 Metametrix Clinical Laboratory Process and method for monitoring gastrointestinal microbiota
CN102940652B (zh) 2008-05-28 2015-03-25 青岛东海药业有限公司 两形真杆菌制剂及其应用
JP2011528117A (ja) 2008-07-15 2011-11-10 メタノミクス ヘルス ゲーエムベーハー 胃バイパス及びそれに関連する状態を診断する手段及び方法
JPWO2010024251A1 (ja) 2008-08-26 2012-01-26 オリンパス株式会社 糞便試料の調製方法、糞便試料調製用溶液、及び採便用キット
WO2010030997A1 (en) 2008-09-12 2010-03-18 The Washington University Regulating intestinal microbiota dependent signaling as a means to modulate body fat and/or weight loss
WO2010036876A2 (en) 2008-09-25 2010-04-01 New York University Compositions and methods for characterizing and restoring gastrointestinal, skin, and nasal microbiota
AU2009320350B2 (en) 2008-11-03 2015-09-24 Tufts University Methods and compositions for inhibiting Clostridium difficile spore germination and outgrowth
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
IT1393931B1 (it) 2009-02-25 2012-05-17 Neuroscienze Pharmaness S C A R L Composizione di spore di batteri non patogeni
EP2432484A1 (en) 2009-04-30 2012-03-28 Compagnie Gervais Danone Use of collinsella aerofaciens for reducing bloating
KR20120015335A (ko) 2009-05-01 2012-02-21 마이크로파마 리미티드 퇴행성 질환의 예방 및 치료를 위한 박테리아 조성물
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
WO2010151842A2 (en) 2009-06-26 2010-12-29 The Regents Of The University Of California Methods and systems for phylogenetic analysis
WO2011046614A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods and systems for phylogenetic analysis
WO2011005756A1 (en) 2009-07-06 2011-01-13 Puretech Ventures, Llc Delivery of agents targeted to microbiota niches
ES2518490T3 (es) 2009-08-18 2014-11-05 Nestec S.A. Una composición nutritiva, la cual comprende cepas de Lactococcus y que reduce los síntomas de alergia, especialmente, en lactantes y en niños
WO2011022542A2 (en) 2009-08-19 2011-02-24 Puretech Ventures, Llc Administration of factors normally present in a microbial niche to improve health
WO2011022660A1 (en) 2009-08-21 2011-02-24 Puretech Ventures, Llc Methods of diagnosing and treating microbiome-associated disease using interaction network parameters
GB0916335D0 (en) 2009-09-17 2009-10-28 Martin W J Medicaments
PL2480255T3 (pl) 2009-09-23 2018-07-31 Thomas Julius Borody Terapia przewlekłych zakażeń jelitowych
WO2011043654A1 (en) 2009-10-05 2011-04-14 Aak Patent B.V. Methods for diagnosing irritable bowel syndrome
US20110081320A1 (en) 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
US20120276149A1 (en) 2009-10-15 2012-11-01 Dan Littman Methods for modulating bacterial infection
PH12012500687A1 (en) 2009-11-12 2012-10-29 Nestec Sa Nutritional composition for promoting gut microbiota balance and health
FI4032586T3 (fi) 2010-02-01 2025-11-25 Ferring Microbiome Inc Bakteeriterapia clostridium difficile -koliittiin
US20130230498A1 (en) 2010-02-16 2013-09-05 Arizona Board Of Regents For And On Behalf Of Arizona State University Reducing short-chain fatty acids and energy uptake in obese humans by managing their intestinal microbial communities
EP2542690A2 (en) 2010-03-01 2013-01-09 Institut National de la Recherche Agronomique Method of diagnostic of inflammatory bowel diseases
AU2011223002B2 (en) 2010-03-01 2015-07-02 Institut National De La Recherche Agronomique Method of diagnostic of obesity
IT1398553B1 (it) 2010-03-08 2013-03-01 Probiotical Spa Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario.
WO2011113801A1 (en) 2010-03-16 2011-09-22 Universiteit Gent Use of clostridium perfringens strain 23 to protect against necrotic enteritis
US8951512B2 (en) 2010-05-04 2015-02-10 New York University Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
EP2591114B1 (en) 2010-07-06 2016-06-08 GlaxoSmithKline Biologicals SA Immunisation of large mammals with low doses of rna
WO2012009712A2 (en) 2010-07-16 2012-01-19 The Board Of Trustees Of The University Of Arkansas Methods and compositions including spore-forming bacteria for increasing the health of animals
FI20105825A7 (fi) 2010-07-26 2012-01-27 Suomen Punainen Risti Veripalvelu Veriryhmästatuksen käyttö III
BR112013002667B1 (pt) 2010-08-04 2020-02-04 Thomas Julius Borody composições para transplante da flora intestinal e métodos para fazê-las e usá-las e dispositivos para administrá-las
US9386793B2 (en) 2010-08-20 2016-07-12 New York University Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
US20130224164A1 (en) * 2010-09-10 2013-08-29 Viropharma Incorporated Environmental Clostridial Bacteriotherapy and Related Formulations and Methods of Manufacture and Use
US20130259899A1 (en) 2010-10-04 2013-10-03 Allen-Vercoe, Emma Molecular And Cellular Biology University Of Guelph Detection of fusobacterium in a gastrointestinal sample to diagnose gastrointestinal cancer
US8802099B2 (en) 2010-11-10 2014-08-12 National Jewish Health Methods to treat allergic conditions
US20120064592A1 (en) 2011-01-26 2012-03-15 Qteros, Inc. Biocatalysts synthesizing deregulated cellulases
US8927252B2 (en) * 2011-02-09 2015-01-06 Lavivo Ab Synbiotic compositions for restoration and reconstitution of gut microbiota
AR085409A1 (es) 2011-02-25 2013-10-02 Tricorder Diagnostics Llc Firmas microbianas como indicadores de exposicon a radiacion
EP3610881A1 (en) 2011-03-09 2020-02-19 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
WO2012122522A2 (en) 2011-03-09 2012-09-13 Washington University Cultured collection of gut microbial community
WO2012142605A1 (en) * 2011-04-15 2012-10-18 Samaritan Health Services Rapid recolonization deployment agent
US20120276056A1 (en) 2011-04-26 2012-11-01 Wieslaw Janusz Bochenek Method for Use of Biologic Agents Including Live or Dormant Forms of Bacteria and other organisms in Treating Infections, Inflammation and Other Diseases of Distal Small Intestine and Large Intestine
WO2012159023A2 (en) 2011-05-19 2012-11-22 Virginia Commonwealth University Gut microflora as biomarkers for the prognosis of cirrhosis and brain dysfunction
US9579353B2 (en) 2011-06-10 2017-02-28 Prothera, Inc. Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes
WO2013008102A2 (en) 2011-07-14 2013-01-17 R.E.D. Laboratories N.V../ S.A. Methods and compositions for evaluating and/or treating chronic immune diseases
US20130022575A1 (en) 2011-07-19 2013-01-24 Microbial Rx Systems and methods of replacing intestinal flora
CA2843388A1 (en) 2011-07-27 2013-01-31 Max International, Llc Compositions comprising sugar-cysteine products
WO2013019896A1 (en) 2011-08-01 2013-02-07 Symbiotix Biotherapies, Inc. Platform for identifying and/or characterizing immunomodulatory agents
JP6116568B2 (ja) 2011-08-30 2017-04-19 アカデミッシュ メディッシュ セントラム インスリン抵抗性を予防および／または処置する方法
CA2848762C (en) 2011-09-14 2021-07-27 Queen's University At Kingston Method for treatment of disorders of the gastrointestinal system
US20130121968A1 (en) 2011-10-03 2013-05-16 Atossa Genetics, Inc. Methods of combining metagenome and the metatranscriptome in multiplex profiles
WO2013066369A2 (en) 2011-10-03 2013-05-10 The Regents Of The University Of Michigan Methods for detecting graft-versus-host disease
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
AU2012322979B2 (en) 2011-10-11 2017-02-02 Achim Biotherapeutics Ab Composition comprising anaerobically cultivated human intestinal microbiota
EP3569690B1 (en) 2011-12-01 2024-08-28 The University of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
GB201201766D0 (en) 2012-02-01 2012-03-14 Imp Innovations Ltd Method
WO2013166031A1 (en) 2012-04-30 2013-11-07 The Washington University Method of isolating and characterizing microorganisms that are targets of host immune responses
EP3686284A1 (en) 2012-05-18 2020-07-29 Genome Research Limited Methods and groups
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
AU2013266069B2 (en) 2012-05-25 2018-03-15 Sloan Kettering Institute For Cancer Research Methods for treating GI syndrome and graft versus host disease
EP2684469A1 (en) 2012-07-13 2014-01-15 Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO Methods for strengthening and assessment of the natural defence of the colon against C. difficile overgrowth
CN104955466A (zh) 2012-11-23 2015-09-30 赛里斯治疗公司 协同细菌组合物和其制造方法和用途
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
KR102222273B1 (ko) 2013-02-04 2021-03-08 세레스 테라퓨틱스, 인코포레이티드 조성물 및 방법
WO2014121304A1 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods
HK1220495A1 (zh) 2013-03-14 2017-05-05 Seres Therapeutics, Inc. 从材料和组合物中检测和富集病原体的方法
WO2014145958A2 (en) 2013-03-15 2014-09-18 Seres Health, Inc. Network-based microbial compositions and methods
JP2016520305A (ja) 2013-05-03 2016-07-14 ネステク ソシエテ アノニム 消化管微生物叢中のラクノスピラ科細菌及び体重との関連性
WO2015018307A1 (en) 2013-08-06 2015-02-12 Bgi Shenzhen Co., Limited Biomarkers for colorectal cancer
EP3074027B1 (en) 2013-11-25 2024-12-18 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
EP3082431A4 (en) 2013-12-16 2017-11-15 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
EP4233884A3 (en) 2015-11-24 2023-10-04 Seres Therapeutics, Inc. Designed bacterial compositions
KR20180094950A (ko) 2015-12-14 2018-08-24 메타보겐 에이비 간내 담즙정체증 및 관련 간 질환들의 치료
AU2017234120B2 (en) 2016-03-14 2024-06-20 Holobiome, Inc. Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
CA3080586A1 (en) 2017-10-30 2019-05-09 Seres Therapeutics, Inc. Compositions and methods for treating antibiotic resistance

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8187590B2 (en) * 1998-08-24 2012-05-29 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US20070141139A1 (en) * 2000-01-27 2007-06-21 Peros Systems Technologies Inc. Composition for intestinal delivery
US20120276201A1 (en) * 2009-12-31 2012-11-01 Ira Milton Trachtman Compositions and method for treatment and prophylaxis of inflammatory bowel disease
US20110189132A1 (en) * 2010-02-01 2011-08-04 Microbios, Inc. Microbial product containing multiple microorganisms

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BOLIVAR, I ET AL.: "Bacterial Diversity In Oral Samples Of Children In Niger With Acute Noma, Acute Necrotizing Gingivitis, And Healthy Controls.", PLOS NEGLECTED TROPICAL DISEASES., vol. 6, no. 3, 6 March 2012 (2012-03-06), pages 1 - 11, XP055264758, DOI: 10.1371/JOURNAL.PNTD.0001556 *
DATABASE NCBI: GENBANK 12 March 2014 (2014-03-12), "Abiotrophia Para-Adiacens Gene For 16S rRNA, partial sequence, strain: Nucleotide", Database accession no. AB022027.1 *
DATABASE NCBI: GENBANK 12 March 2014 (2014-03-12), Database accession no. AM420133.1 *
KANAMOTO, T ET AL.: "Genetic Heterogeneities And Phenotypic Characteristics Of Strains Of The Genus Abiotrophia And Proposal Of Abiotrophia Para-Adiacens Sp. Nov.", JOURNAL OF CLINICAL MICROBIOLOGY., vol. 38, no. 2, 1 February 2000 (2000-02-01), pages 492 - 498, XP055264763 *
MYLLYLUOMA, E ET AL.: "Effects Of Multispecies Probiotic Combination On Helicobacter pylori Infection In Vitro.", CLINICAL AND VACCINE IMMUNOLOGY., vol. 15, no. 9, 1 September 2008 (2008-09-01), pages 1472 - 1482, XP055264754, DOI: 10.1128/CVI.00080-08 *
WANG, M ET AL.: "Comparison Of Bacterial Diversity Along The Human Intestinal Tract By Direct Cloning And Sequencing Of 16S rRNA Genes.", FEMS MICROBIOLOGY ECOLOGY., vol. 54, no. 2, 1 October 2005 (2005-10-01), pages 219 - 231, XP027780004 *

Cited By (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12303537B2 (en) 2010-02-01 2025-05-20 Ferring Microbiome Inc. Bacteriotherapy for clostridium difficile colitis
US11986500B2 (en) 2010-02-01 2024-05-21 Rebiotix Inc Bacteriotherapy for clostridium difficile colitis
US12102655B2 (en) 2010-02-01 2024-10-01 Rebiotix Inc. Bacteriotherapy for clostridium difficile colitis
US11013773B2 (en) 2011-07-14 2021-05-25 4D Pharma Research Limited Lactic acid bacterial strains
US11266698B2 (en) 2011-10-07 2022-03-08 4D Pharma Research Limited Bacterium for use as a probiotic for nutritional and medical applications
US10149867B2 (en) 2012-02-29 2018-12-11 The General Hospital Corporation Compositions of microbiota and methods related thereto
US10149870B2 (en) 2012-02-29 2018-12-11 The General Hospital Corporation Compositions of microbiota and methods related thereto
US11590176B2 (en) 2012-02-29 2023-02-28 Johnson & Johnson Consumer Inc. Compositions of microbiota and methods related thereto
US10729732B2 (en) 2012-02-29 2020-08-04 Ethicon Endo Surgery, Inc. Compositions of microbiota and methods related thereto
US12048721B2 (en) 2012-02-29 2024-07-30 The General Hospital Corporation Compositions of microbiota and methods related thereto
US9533014B2 (en) 2012-11-23 2017-01-03 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US11458173B2 (en) 2012-11-23 2022-10-04 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US10864235B2 (en) 2012-11-23 2020-12-15 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US11458174B2 (en) 2012-11-23 2022-10-04 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US11389490B2 (en) 2012-11-23 2022-07-19 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US12083151B2 (en) 2012-11-23 2024-09-10 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US11464812B2 (en) 2012-11-23 2022-10-11 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US9585921B2 (en) 2013-02-04 2017-03-07 Seres Therapeutics, Inc. Compositions and methods
US10973861B2 (en) 2013-02-04 2021-04-13 Seres Therapeutics, Inc. Compositions and methods
US9855303B2 (en) 2013-02-04 2018-01-02 Seres Therapeutics, Inc. Compositions and methods
EP3584308A3 (en) * 2013-02-04 2020-03-04 Seres Therapeutics, Inc. Compositions and methods
US11185562B2 (en) 2013-02-04 2021-11-30 Seres Therapeutics, Inc. Compositions and methods for inhibition of pathogenic bacterial growth
US10064900B2 (en) 2013-02-04 2018-09-04 Seres Therapeutics, Inc. Methods of populating a gastrointestinal tract
US10064901B2 (en) 2013-02-04 2018-09-04 Seres Therapeutics, Inc. Compositions and methods
US9446080B2 (en) 2013-02-04 2016-09-20 Seres Therapeutics, Inc. Compositions and methods
US11730775B2 (en) 2013-02-04 2023-08-22 Seres Therapeutics, Inc. Methods for treatment of Clostridium difficile infection or recurrence or symptoms thereof
US10967011B2 (en) 2013-02-04 2021-04-06 Seres Therapeutics, Inc. Compositions and methods
EP3587558A3 (en) * 2013-02-04 2020-03-04 Seres Therapeutics, Inc. Methods of populating a gastrointestinal tract
US11666612B2 (en) 2013-03-15 2023-06-06 Seres Therapeutics, Inc Network-based microbial compositions and methods
US10076546B2 (en) 2013-03-15 2018-09-18 Seres Therapeutics, Inc. Network-based microbial compositions and methods
US10881696B2 (en) 2013-03-15 2021-01-05 Seres Therapeutics, Inc. Network-based microbial compositions and methods
US11414463B2 (en) 2013-04-10 2022-08-16 4D Pharma Research Limited Polypeptide and immune modulation
US10851137B2 (en) 2013-04-10 2020-12-01 4D Pharma Research Limited Polypeptide and immune modulation
US10603341B2 (en) 2013-06-05 2020-03-31 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10624932B2 (en) 2013-06-05 2020-04-21 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10610547B2 (en) 2013-06-05 2020-04-07 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US11554143B2 (en) 2013-06-05 2023-01-17 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9433651B2 (en) 2013-06-05 2016-09-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10391129B2 (en) 2013-06-05 2019-08-27 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10434125B2 (en) 2013-06-05 2019-10-08 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10434124B2 (en) 2013-06-05 2019-10-08 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10434126B2 (en) 2013-06-05 2019-10-08 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10688137B2 (en) 2013-06-05 2020-06-23 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10471107B2 (en) 2013-06-05 2019-11-12 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9675648B2 (en) 2013-06-05 2017-06-13 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9642880B2 (en) 2013-06-05 2017-05-09 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10493111B2 (en) 2013-06-05 2019-12-03 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10633714B2 (en) 2013-07-21 2020-04-28 Pendulum Therapeutics, Inc. Methods and systems for microbiome characterization, monitoring and treatment
US11918612B2 (en) 2013-11-25 2024-03-05 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US11266699B2 (en) 2013-11-25 2022-03-08 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US12409197B2 (en) 2013-11-25 2025-09-09 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US10258655B2 (en) 2013-11-25 2019-04-16 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
US10668116B2 (en) 2014-10-31 2020-06-02 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
US9486487B2 (en) 2014-10-31 2016-11-08 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
US11213556B2 (en) 2014-10-31 2022-01-04 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
US10842830B2 (en) 2014-10-31 2020-11-24 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
US11278580B2 (en) 2014-10-31 2022-03-22 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
US11364270B2 (en) 2014-10-31 2022-06-21 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
US11931387B2 (en) 2014-10-31 2024-03-19 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
US10842831B2 (en) 2014-10-31 2020-11-24 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
US10675312B2 (en) 2014-10-31 2020-06-09 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
US10973872B2 (en) 2014-12-23 2021-04-13 4D Pharma Research Limited Pirin polypeptide and immune modulation
US10456444B2 (en) 2014-12-23 2019-10-29 4D Pharma Research Limited Pirin polypeptide and immune modulation
US11723933B2 (en) 2014-12-23 2023-08-15 Cj Bioscience, Inc. Composition of bacteroides thetaiotaomicron for immune modulation
US11642381B2 (en) 2015-06-09 2023-05-09 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10226431B2 (en) 2015-06-09 2019-03-12 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US11654164B2 (en) 2015-06-09 2023-05-23 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10391064B2 (en) 2015-06-09 2019-08-27 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US12036250B2 (en) 2015-06-09 2024-07-16 Rebiotix Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10391130B2 (en) 2015-06-15 2019-08-27 4D Pharma Research Limited Compositions comprising bacterial strains
US11389493B2 (en) 2015-06-15 2022-07-19 4D Pharma Research Limited Compositions comprising bacterial strains
US11433106B2 (en) 2015-06-15 2022-09-06 4D Pharma Research Limited Compositions comprising bacterial strains
US10780134B2 (en) 2015-06-15 2020-09-22 4D Pharma Research Limited Compositions comprising bacterial strains
US10864236B2 (en) 2015-06-15 2020-12-15 4D Pharma Research Limited Compositions comprising bacterial strains
US11040075B2 (en) 2015-06-15 2021-06-22 4D Pharma Research Limited Compositions comprising bacterial strains
US10744167B2 (en) 2015-06-15 2020-08-18 4D Pharma Research Limited Compositions comprising bacterial strains
US11273185B2 (en) 2015-06-15 2022-03-15 4D Pharma Research Limited Compositions comprising bacterial strains
US10736926B2 (en) 2015-06-15 2020-08-11 4D Pharma Research Limited Compositions comprising bacterial strains
US20170354695A1 (en) * 2015-06-15 2017-12-14 4D Pharma Research Limited Compositions comprising bacterial strains
US10493112B2 (en) 2015-06-15 2019-12-03 4D Pharma Research Limited Compositions comprising bacterial strains
US11331352B2 (en) 2015-06-15 2022-05-17 4D Pharma Research Limited Compositions comprising bacterial strains
US20200138874A1 (en) * 2015-06-15 2020-05-07 4D Pharma Research Limited Compositions comprising bacterial strains
US10322151B2 (en) 2015-06-15 2019-06-18 4D Pharma Research Limited Compositions comprising bacterial strains
US10500237B2 (en) 2015-06-15 2019-12-10 4D Pharma Research Limited Compositions comprising bacterial strains
CN108348558A (zh) * 2015-07-08 2018-07-31 赛里斯治疗公司 治疗结肠炎的方法
WO2017008026A1 (en) * 2015-07-08 2017-01-12 Seres Therapeutics, Inc. Methods of treating colitis
CN105012350B (zh) * 2015-08-06 2018-09-25 温州医科大学 益生菌丁酸梭菌菌株
CN105012350A (zh) * 2015-08-06 2015-11-04 温州医科大学 益生菌丁酸梭菌菌株
KR102726075B1 (ko) * 2015-08-11 2024-11-04 유니베르시타트 데 지로나 패칼리박테리움 프라우스니치이 파일로군 i /또는 파일로군 ii 구성원을 정량하는 방법 및 바이오마커로서의 그 용도
KR20180048696A (ko) * 2015-08-11 2018-05-10 유니베르시타트 데 지로나 패칼리박테리움 프라우스니치이 파일로군 i /또는 파일로군 ii 구성원을 정량하는 방법 및 바이오마커로서의 그 용도
US11058732B2 (en) 2015-11-20 2021-07-13 4D Pharma Research Limited Compositions comprising bacterial strains
US10471108B2 (en) 2015-11-20 2019-11-12 4D Pharma Research Limited Compositions comprising bacterial strains
US10610550B2 (en) 2015-11-20 2020-04-07 4D Pharma Research Limited Compositions comprising bacterial strains
US10391128B2 (en) 2015-11-23 2019-08-27 4D Pharma Research Limited Compositions comprising bacterial strains
US10744166B2 (en) 2015-11-23 2020-08-18 4D Pharma Research Limited Compositions comprising bacterial strains
US11045506B2 (en) 2015-11-24 2021-06-29 Memorial Sloan-Kettering Cancer Center Methods and compositions for identifying and treating subjects at risk for checkpoint blockade therapy associated colitis
WO2017091694A1 (en) * 2015-11-24 2017-06-01 Memorial Sloan-Kettering Cancer Center Methods and compositions for identifying and treating subjects at risk for checkpoint blockade therapy associated colitis
CN109661236A (zh) * 2015-11-24 2019-04-19 赛里斯治疗公司 设计的细菌组合物
RU2773327C2 (ru) * 2015-11-24 2022-06-02 Серес Терапеутикс, Инк. Разработанные бактериальные композиции
WO2017091783A3 (en) * 2015-11-24 2017-07-13 Seres Therapeutics, Inc. Designed bacterial compositions
EP4233884A3 (en) * 2015-11-24 2023-10-04 Seres Therapeutics, Inc. Designed bacterial compositions
US11197897B2 (en) 2015-11-25 2021-12-14 Memorial Sloan Kettering Cancer Center Methods and compositions for reducing vancomycin-resistant enterococci infection or colonization
WO2017091753A1 (en) * 2015-11-25 2017-06-01 Memorial Sloan-Kettering Cancer Center Methods and compositions for reducing vancomycin-resistant enterococci infection or colonization
US20180256653A1 (en) * 2015-11-25 2018-09-13 Memorial Sloan-Kettering Cancer Center Methods and compositions for reducing vancomycin-resistant enterococci infection or colonization
AU2016361583B2 (en) * 2015-11-25 2021-05-13 Memorial Sloan-Kettering Cancer Center Methods and compositions for reducing vancomycin-resistant enterococci infection or colonization
US10646520B2 (en) 2015-11-25 2020-05-12 Memorial Sloan Kettering Cancer Center Methods and compositions for reducing vancomycin-resistant Enterococci infection or colonization
US10583158B2 (en) 2016-03-04 2020-03-10 4D Pharma Plc Compositions comprising bacterial strains
US12390498B2 (en) 2016-06-14 2025-08-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
US10064904B2 (en) 2016-06-14 2018-09-04 Vedanta Biosciences, Inc. Treatment of Clostridium difficile infection
US11701396B2 (en) 2016-06-14 2023-07-18 Vedanta Biosciences, Inc. Treatment of Clostridium difficile infection
US9999641B2 (en) 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
US10350250B2 (en) 2016-06-14 2019-07-16 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
US10555980B2 (en) 2016-06-14 2020-02-11 Vedanta Biosciences, Inc. Treatment of Clostridium difficile infection
US10456431B2 (en) 2016-06-14 2019-10-29 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
US10610549B2 (en) 2016-07-13 2020-04-07 4D Pharma Plc Composition comprising bacterial strains
US10960031B2 (en) 2016-07-13 2021-03-30 4D Pharma Plc Compositions comprising bacterial strains
US10610548B2 (en) 2016-07-13 2020-04-07 4D Pharma Plc Compositions comprising bacterial strains
US11224620B2 (en) 2016-07-13 2022-01-18 4D Pharma Plc Compositions comprising bacterial strains
US10967010B2 (en) 2016-07-13 2021-04-06 4D Pharma Plc Compositions comprising bacterial strains
CN109072173A (zh) * 2016-09-06 2018-12-21 深圳华大生命科学研究院 克里斯坦森氏菌(Christensenella intestinihominis)及其应用
US10543238B2 (en) 2016-12-12 2020-01-28 4D Pharma Plc Compositions comprising bacterial strains
US10485830B2 (en) 2016-12-12 2019-11-26 4D Pharma Plc Compositions comprising bacterial strains
US10898526B2 (en) 2016-12-12 2021-01-26 4D Pharma Plc Compositions comprising bacterial strains
WO2018172483A1 (en) * 2017-03-22 2018-09-27 Assistance Publique - Hopitaux De Paris Method for determining the potential efficacy of anticancer treatment
US11376284B2 (en) 2017-05-22 2022-07-05 4D Pharma Research Limited Compositions comprising bacterial strains
US11382936B2 (en) 2017-05-22 2022-07-12 4D Pharma Research Limited Compositions comprising bacterial strains
US11123378B2 (en) 2017-05-22 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US10987387B2 (en) 2017-05-24 2021-04-27 4D Pharma Research Limited Compositions comprising bacterial strain
US11779613B2 (en) 2017-06-14 2023-10-10 Cj Bioscience, Inc. Compositions comprising a bacterial strain of the genus Megasphera and uses thereof
US12048720B2 (en) 2017-06-14 2024-07-30 Cj Bioscience, Inc. Compositions comprising bacterial strains
US11007233B2 (en) 2017-06-14 2021-05-18 4D Pharma Research Limited Compositions comprising a bacterial strain of the genus Megasphera and uses thereof
US11660319B2 (en) 2017-06-14 2023-05-30 4D Pharma Research Limited Compositions comprising bacterial strains
US11123379B2 (en) 2017-06-14 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US11701394B2 (en) 2017-08-14 2023-07-18 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
US12233095B2 (en) 2017-08-30 2025-02-25 Pendulum Therapeutics Inc Methods and compositions for treatment of microbiome associated disorders
US11583558B2 (en) 2017-08-30 2023-02-21 Pendulum Therapeutics, Inc. Methods and compositions for treatment of microbiome-associated disorders
US12214002B2 (en) 2017-10-30 2025-02-04 Seres Therapeutics, Inc. Compositions and methods for treating antibiotic resistance
US11369644B2 (en) 2018-04-10 2022-06-28 Siolta Therapeutics, Inc. Microbial consortia
US11419902B2 (en) 2018-05-11 2022-08-23 4D Pharma Research Limited Compositions comprising bacterial strains
US12343360B2 (en) 2018-07-19 2025-07-01 Pendulum Therapeutics Inc Methods and compositions for microbial engraftment
US12161680B2 (en) 2018-08-17 2024-12-10 Vedanta Biosciences, Inc. Methods of decreasing dysbiosis and restoring a microbiome
US12478649B2 (en) * 2019-01-31 2025-11-25 The Chinese University Of Hong Kong Therapeutic and prophylactic treatment for colorectal cancer
IT201900006056A1 (it) * 2019-04-18 2020-10-18 Probiotical Spa Procedimento per la preparazione di una biomassa di cellule di batteri liofilizzate stabili e determinazione della loro stabilità mediante un metodo citofluorimetrico
US11406675B2 (en) 2019-10-07 2022-08-09 Siolta Therapeutics, Inc. Therapeutic pharmaceutical compositions
EP4102984A4 (en) * 2020-02-10 2024-06-26 Native Microbials, Inc. MICROBIAL COMPOSITIONS AND METHODS OF USE FOR CANINE ENTEROPATHY AND DYSBIOSIS
US12180464B2 (en) 2020-02-10 2024-12-31 Native Microbials, Inc. Microbial compositions and methods of use for canine enteropathy and dysbiosis
WO2021163212A1 (en) * 2020-02-10 2021-08-19 Native Microbials, Inc. Microbial compositions and methods of use for canine enteropathy and dysbiosis
WO2021183701A1 (en) * 2020-03-10 2021-09-16 Federation Bio Inc. Microbial consortia for the treatment of disease
CN111991404A (zh) * 2020-10-10 2020-11-27 西南医科大学 防治真菌感染的复合维生素d及其应用
EP4250932A4 (en) * 2020-11-25 2025-07-30 Seres Therapeutics Inc BACTERIAL COMPOSITIONS DESIGNED TO TREAT GRAFT-VERSE-HOST DISEASE
WO2023283681A1 (en) * 2021-07-10 2023-01-19 Microba Ip Pty Ltd Compositions and methods for treating disease ii
WO2023199057A1 (en) 2022-04-13 2023-10-19 Brunel University London Compositions for preventing and treating infection comprising an artificial sweetener

Also Published As

Publication number Publication date
EP4233545A3 (en) 2023-10-18
KR102426653B1 (ko) 2022-07-28
JP2019135240A (ja) 2019-08-15
AU2020201598B2 (en) 2022-03-24
MX2015006491A (es) 2015-12-03
AU2024204663A1 (en) 2024-08-01
EP2953472A1 (en) 2015-12-16
AU2018204406A1 (en) 2018-07-05
IL238973A0 (en) 2015-07-30
ES2949659T3 (es) 2023-10-02
CA2892297C (en) 2023-10-24
RU2724666C2 (ru) 2020-06-25
AU2018204406B2 (en) 2019-12-05
KR102617655B1 (ko) 2023-12-27
JP2015537042A (ja) 2015-12-24
JP2022028787A (ja) 2022-02-16
CA2892297A1 (en) 2014-05-30
US20230226126A1 (en) 2023-07-20
KR20150108357A (ko) 2015-09-25
BR112015011933A8 (pt) 2022-09-20
EP4233545A2 (en) 2023-08-30
US20250064869A1 (en) 2025-02-27
SG10201704035TA (en) 2017-06-29
AU2013347805A1 (en) 2015-07-09
RU2015124366A (ru) 2017-01-10
AU2020201598A1 (en) 2020-03-19
HK1218836A1 (zh) 2017-03-17
DK3628161T3 (da) 2023-05-30
CN104955466A (zh) 2015-09-30
CA3212215A1 (en) 2014-05-30
PT3628161T (pt) 2023-05-15
JP2024129008A (ja) 2024-09-26
AU2020201598C1 (en) 2022-07-07
JP7491643B2 (ja) 2024-05-28
JP6978463B2 (ja) 2021-12-08
EP3628161B1 (en) 2023-04-05
KR20220108205A (ko) 2022-08-02
AU2022204478A1 (en) 2022-07-14
AU2013347805B2 (en) 2018-04-05
EP2953472A4 (en) 2017-03-01
JP6506173B2 (ja) 2019-04-24
EP3628161A1 (en) 2020-04-01
CA3212772A1 (en) 2014-05-30
NZ709392A (en) 2016-10-28
BR112015011933A2 (pt) 2018-05-15
SG11201503966PA (en) 2015-06-29
FI3628161T3 (fi) 2023-05-25
US12083151B2 (en) 2024-09-10
AU2013347805C1 (en) 2018-06-28
PL3628161T3 (pl) 2023-08-07

Similar Documents

Publication Publication Date Title
US12083151B2 (en) Synergistic bacterial compositions and methods of production and use thereof
US11464812B2 (en) Synergistic bacterial compositions and methods of production and use thereof
JP7409743B2 (ja) 病原性細菌生育の抑制のための組成物および方法
EP3074027B1 (en) Synergistic bacterial compositions and methods of production and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13856249

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 238973

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2892297

Country of ref document: CA

Ref document number: 2015544179

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/006491

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 122022018246

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20157016626

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2015124366

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2013856249

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013347805

Country of ref document: AU

Date of ref document: 20131125

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015011933

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112015011933

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150525